

THE UNIVERSITY OF BRITISH COLUMBIA
Curriculum Vitae

Date: Feb 2015

1. **SURNAME:** GILKS **FIRST NAME:** Cyril
MIDDLE NAME(S): Blake
2. **DEPARTMENT/SCHOOL:** DEPARTMENT OF PATHOLOGY AND LABORATORY MEDICINE
3. **FACULTY:** MEDICINE
4. **PRESENT RANK:** PROFESSOR **SINCE:** July 2005
5. **POST-SECONDARY EDUCATION**

University or Institution	Degree	Subject Area	Dates
University of New Brunswick	BSc		1975-78
Dalhousie University	M.D. cum laude	Medicine	1978-82
Royal Columbian Hospital	Rotating Internship		1982-83
University of British Columbia	Resident	Anatomic Pathology	1985-88
Harvard University	Fellow	Pathology	1988
Fox Chase Cancer Centre, Philadelphia	Fellow	Pathology	1989-91

Special Professional Qualifications

Fellow of the Royal College of Physicians and Surgeons of Canada (Anatomical Pathology)

6. **EMPLOYMENT RECORD**

(a) *Prior to coming to UBC*

University, Company or Organization	Rank or Title	Dates
University of British Columbia	Locum tenens, general practice	1983-84
	Locum tenens, anatomical pathology	1987

(b) *At UBC (University Hospital until 2001, then Vancouver General Hospital)*

Rank or Title	Dates
Pathologist	1991-present
Associate Director of Laboratories (for UBC site)	1996-2001
Assistant Professor	1991-1997
Associate Professor	1997-2005
Professor	2005-present

Co-Director, Genetic Pathology Evaluation Centre Associate Medical Director of Laboratories and Anatomic Pathology Division Head, Vancouver General Hospital Co-director, Canadian Immunohistochemistry Quality Control program Acting Head, Dept of Pathology and Laboratory Medicine, UBC Interim medical director of laboratories and Department Head, Dept of Pathology and Laboratory Medicine, Vancouver Coastal Health	2001-present 2006-2009, 2010 to 2015 2007-present 2009-2010 2015 to present
---	---

(c) *Date of granting of tenure at U.B.C.: July 1, 1997*

7. **LEAVES OF ABSENCE**

University, Company or Organization at which Leave was taken	Type of Leave	Dates
Kijabe Medical Center, Kijabe, Kenya	Educational	Oct., 1997

8. **TEACHING**

(a) *Areas of special interest and accomplishments*

Breast and Gynecological Pathology
Teaching Pathology, Surgery and Obstetrics and Gynecology residents
Development of Pathology labs for the GI/Nutrition block of the new medical school curriculum

(b) *Courses Taught at UBC*

Session	Course Number	Scheduled Hours	Class Size	Hours Taught			
				Lectures	Tutorials	Labs	Other
1993-97	Path 401	8	40	1	7		
1991-93	Path 301	20	25	20			
1992-97	Path 500	2	15	2			
1994-current	Path 406	4	15	4			
1992, 1998, 2002	Path 438	Supervise and examine honors/directed studies BMLSc students					
1995	Biochem 521	2		2			
1995-97	Biochem 400	1	120	1			
1996-2000	Path 541	12	4	4		8	
1998-current	Path 548	4	8	4			

1998-2008	Undergrad medical	2	160			2	
1998-current	Undergrad medical	6	16			6	
1999-current	Path 304	4	10	1		3	
2000-2006	Obst 506	1	10	1			
2003-2006	Undergrad medical	2	160	2			
2009	Obst 506	1	10	1			

Also Academic Advisor to a group of medical students (1997-2000)

(c) *Graduate Students Supervised*

Student Name	Program Type	Year		Principal Supervisor	Co-Supervisor(s)
		Start	Finish		
Carol Thurley	MSc	1992	1996	Dr. B. Gilks	
Ed Wong	PhD	1993	1999	Dr. B. Gilks	Dr. S. Porter
Raj Dhani	PhD	1994	1999	Dr. B. Gilks	Dr. A. Churg
B. Susnik	PhD		1992	Member of examining committee	
S. Ghaffari	PhD		1993	"	
A. Bradley	PhD		1994	"	
S. Nehr	MSc	1991	1993	Member of supervisory committee	
L. Ailles	PhD	1993	1999	"	
G. Bebb	PhD		1997	Member of examining committee	
K. Omari	PhD		1997	"	
P.M. Curry	PhD		1997	"	
E. Coneally	PhD		1998	"	
K. Zay	MSc	1997		"	
K. Dentremont	MSc		1998	"	
Maz Badii (summer student)	MD	1992	1992	Dr. B. Gilks	
Robin Kennie (summer student)	MD	1996	1996	Dr. B. Gilks	
Y. Guan	PhD		1998	Member of examining committee	
A. Rempel	MSc		1998	"	
M. Li	PhD		2000	"	
S. Longus	PhD		2000	"	
A. Siowak	MSc		2002	"	
L. Brown	MSc	2001		Member of supervisory committee	
T. Ota	PhD	2002	2006	"	

Forrest Hsu	MD summer student	2000		Blake Gilks	
Mohsen Al-Kushi	MSc	2000	2002	Blake Gilks	
Nicholas Au (summer student)	MD		2002	Blake Gilks	
M. Woo	PhD		2003	Member of examining committee	
Josh Press	MSc	2004	2007	Blake Gilks (co-supervisor with D Huntsman)	D Huntsman
Jody Ralph	PhD		2004	Member of examining committee	
Tracy Tucker	PhD		2006	Member of examining committee	
Maggie Cheang	PhD	2005		Member of supervisory committee	
Hisae Nakamura	PhD	2006	2011	Member of supervisory committee	
Dong Lin	PhD	2005	2011	Member of supervisory committee	
Alvin Ng	MSc	2006	2007	Member of supervisory committee	
Jane Cippolone	MSc	2004	2006	Member of supervisory committee	
Marcia McCoy	PhD	2003	2009	Member of supervisory committee	
Kelvin So	PhD	2006	2012	Member of supervisory committee	
Jefferson Terry	PhD	2004	2008	Torsten Nielsen	Blake Gilks
Jon Carrick	BSc (summer student)		2007	Blake Gilks	
Henry Porter	BSc (summer student)		2008	Blake Gilks	
Melanie Lehman	PhD		2008	Member of examining committee	
Jordan Cheng	PhD	2008	2012	Member of supervisory committee	
Kim Wiegand	PhD	2008	2013	David Huntsman	Blake Gilks
Peter Kim	PhD		2011	Member of examining committee	

Kevin Yang	PhD	2009		Member of supervisory committee	
Jay Gundawara	PhD	2009		Member of supervisory committee	
Xin Qiu	PhD	2010		Member of supervisory committee	
Daphne Cheung	summer student, BMLSc program	2013		B Gilks	
Kimberley Snyder	MSc		2014	Member of examining committee	

Also - primary supervisor of clinical fellows in gynecological pathology: M Kobel, R Parker, C Ludwick, B Clarke, O Algha, R Al Bannai, G Elomami

(d) *Continuing Education Activities*

Up to date with Royal College MOCOMP program

(e) *Visiting Lecturer (indicate university/organization and dates)*

Netherlands Cancer Institute, April 1993

(f) *Other*

Host Scientist for visiting Chinese physician/scientist, Dr. Lu Fangen, through World University Service of Canada/CIDA, 1993-1994

9. SCHOLARLY AND PROFESSIONAL ACTIVITIES

(a) *Areas of special interest and accomplishments*

Gynecological Pathology

(b) *Research or equivalent grants (indicate under Comp whether grants were obtained competitively (C) or non-competitively (NC))*

Granting Agency	Subject	Comp	\$ Per Year	Year	Principal Investigator	Co-Investigator(s)
BCHRF	Genetic Analysis of progression of T cell lymphoma cell lines to IL-2 Independent growth	Y	\$39,500	1991-93	Dr. B. Gilks	
University Hospital Foundation	T-cell receptor variable region gene expression in immune-mediated bowel disease	Y	\$28,500	1992	Dr. B. Gilks	

NCIC(C)	Characterization of the Gfi-1 gene	Y	\$63,100	1994-97	Dr. B. Gilks	
BCHRF	Role of elastase in the pathogenesis of emphysema	Y	\$43,050	1994-96	Dr. B. Gilks	
BCHRF	Prevention of cigarette smoke induced emphysema, etc.	Y	\$44,000	1995-97	Dr. J. Wright	Dr. B. Gilks Dr. S. Porter
MRC	Prevention of cigarette smoke induced emphysema, etc.	Y	\$63,378	1996-99	Dr. J. Wright	Dr. B. Gilks Dr. S. Porter
MRC	Mechanisms of mineral particle uptake by pulmonary epithelial cells	Y	\$76,872	1997-2002	Dr. A. Churg	Dr. B. Gilks Dr. J.L. Wright
BC Lung	Clonal heterogeneity of antioxidant enzyme expression in the lung	Y	\$20,050	1997-1998	Dr. B. Gilks	
Bayer/ Red Cross R&D Fund	Efficacy of alpha-1-proteinase inhibitor in prevention of etc.	Y	\$57,000	1997-1998	Dr. B. Gilks	
Bayer Blood Partnership Fund	Efficacy of Alpha1-Proteinase Inhibitor in the Prevention of Acute and Chronic Lung Injury	Y	\$75,000	1999-2001	Dr. B. Gilks	
Vancouver Hospital Foundation Special Opportunities Research Fund	Biomarker Assessment in ovarian cancer	Y	45,362	2003-4	B Gilks	
National Ovarian Cancer Ass'n	Operation of a Tumor Bank for Ovarian Cancer	Y	\$16,000	2000-2004	B. Gilks	N. Auersperg
Vancouver General Hospital Professional Development Fund	Creation of a Tissue Microarray Lab	Y	\$100,000	2002-2003	D. Huntsman	B. Gilks
Aventis Pharma Canada	Creation of clinically annotated tissue microarrays	N	\$250,000	2003-2008	D. Huntsman	B. Gilks
Breast Cancer Translational Acceleration Grant (CIHR/CBCRI)	A comprehensive testing strategy for the integration of novel biomarkers into early breast cancer care	Y	135,000	2003-2008	B. Norris and B. Gilks (Co-principal investigators)	
Michael Smith Health Research Foundation	Unit Grant to support Genetic Pathology Evaluation Centre	Y	144,016	2004-2008	D. Huntsman	B. Gilks and T. Nielsen
Michael Smith Foundation for Health Research	Improving outcomes for women with cancer through rapid validation of new biomarkers	Y	576,064	2004-2007		
Vancouver Coastal Health Authority	Biomarker assessment of ovarian cancer	Y	43,362	2003-2004		

National Cancer Institute of Canada	Frequency and Clinical Significance of Functional Loss of Proteins Involved in DNA Double Strand Break Repair in Ovarian Cancer	Y	115,000	2006-2008	B. Gilks	D. Huntsman
Michael Smith Foundation for Health Research	Unit grant to OvCaRe (ovarian cancer research)	Y	200,000	2007-2011	B Gilks	
BC Yukon Breast Ca Foundation	Clinical Testing for Basal-like Breast Cancer	Y	165,000	2011-2013	B. Gilks	T. Nielsen
CIHR	Clinical and Functional Significance of a Pathognomonic FOXL2 Mutation in Granulosa Cell Tumours of the Ovary	Y	134,749	2009-13	D Huntsman	B Gilks
CIHR	5-Mutations in the SWI/SNF Chromatin Remodeling Complex Genes: An Alternative Mechanism for Ovarian Carcinogenesis	Y	168,902	2010-2014	D Huntsman	B Gilks ←
CIHR	6-Genomic Disruption in High-Grade Serous Ovarian Carcinomas: Steady State or Continuous Drift? 5-	Y	174,947	2011-2015	J McAlpine	B Gilks ←
CPACC	External quality assurance and proficiency testing for cancer biomarkers in Canadian clinical diagnostic laboratories, and a program for introduction of new diagnostic tests into labs across Canada: Delivering on the promise of personalized medicine 6-	Y	123,512	2014-2018	B Gilks	←

Formateret: Punkttopstilling

Formateret: Punkttopstilling

Formateret: Punkttopstilling

(c) Research or equivalent contracts (indicate under COMP whether grants were obtained competitively (C) or non-competitively (NC)).

Granting Agency	Subject	COMP	\$ Per Year	Year	Principal Investigator	Co-Investigator(s)

(d) Invited Presentations

Okanagan Pathology Associates - "Endometrial Pathology", April 1992

Vancouver Chapter, Canadian Coeliac Association - "Coeliac disease and immune recognition", January, 1994

University of California San Francisco - "Cloning and characterization of the Gfil gene", March 1994

Canadian Congress of Laboratory Technology - "Molecular Biology and Molecular Diagnostics", June, 1994

Vancouver Cytotechnology discussion group - "Molecular Diagnostics", October 1994

Whistler Anatomic Pathology Meeting - "Smooth muscle tumors of the uterus", February 1995

B.C. Society of Medical Technologists - "Molecular Diagnostics and Anatomic Pathology", October 1996

Paediatric Pathology Rounds - "Role of Gfil in lymphomagenesis and immune dysfunction", March 1998

Society of Obstetricians and Gynecologists of Canada - "Ovarian Borderline Tumors: Pathological Aspects", June 1998

DABoyes Society - "Non-squamous cervix cancers" November 1998

Histotechnology Education Day - "Molecular diagnosis in Gynecological Pathology", May 1999

Dept. Of Obstetrics and Gynecology - "Gyne Path review", Jan 2000 and Feb 2000

Dept. Of Plastic Surgery - "Breast Pathology for Plastic Surgeons", Feb 2000

Dept. Of Radiation Oncology - "Gyne Path review", April 2000

International Academy of Pathology, Hong Kong Division - "Gynecological Pathology: selected topics" Sept 2000

Association of Directors of Pathology of China - "Gynecological Pathology: selected topics" Sept 2000

Dr. C.J.Coady Pathology Associates - "Endometrial hyperplasia and adenocarcinoma" - Nov 2000

Dept of Obstetrics and Gynecology Grand Rounds - "Ovarian Tumor Banking" - Oct 2001

DABoyes Society - "Rare Gynecological Cancers", November 2001

Whistler Anatomic Pathology Meeting - "Endometrial Carcinoma", February 2002

Gynecological Pathology Slide Seminar, Dept of Pathology, Stanford University, March 2002

Ovarian Sex Cord Tumors, Dept of Pathology, Stanford University, March 2002

Dept of Obstetrics and Gynecology Grand Rounds - "Microarray studies of ovarian carcinoma", May 2003

Canadian Association of Pathologists meeting - "The role of the surgical pathologist in guiding individualized patient care in gynecologic oncology", July 2003

Canadian Association of Pathologists meeting - "Applications of micro-arrays in diagnostic pathology", July 2003

Dept of Obstetrics and Gynecology Grand Rounds - "Mucinous ovarian tumors:", Feb 2004

Fox Chase Cancer Center, Philadelphia PA, Ovarian Cancer Research Seminar Series - "Subclassification of human epithelial malignancies by hierarchical clustering analysis of immunostaining data", May 2004

Queens University, Dept of Pathology - "Subclassification of human epithelial malignancies by hierarchical clustering analysis of immunostaining data", May 2004

Association of Directors of Pathology of China - "Microarrays in Pathology", July 2004

Hong Kong International Academy of Pathology - "Advances in the pathology of ovarian cancer", July 2004

University of Calgary, Dept of Pathology - "Subclassification of human epithelial malignancies by hierarchical clustering analysis of immunostaining data", Oct 2004

Stanford University, Dept of Pathology - "Subclassification of human epithelial malignancies by hierarchical clustering analysis of immunostaining data", Nov 2004

DABoyes Society - "Genetic abnormalities in ovarian cancer", November 2004

Memorial Sloan Kettering Cancer Center, NY, "Sub-classification of Ovarian Surface Epithelial Carcinomas Based on a Combination of Morphology and Molecular Abnormalities", May 2006

Prince George Regional Hospital - "Use of immunohistochemistry in diagnostic surgical pathology", Aug 2006

University of Victoria/BCCA - "Host immune response in Ovarian Carcinoma", Jan 2007

University of Calgary - "Subclassification of Ovarian Carcinoma Based on a Combination of Molecular and Morphological Features" - March 2007

University of Leipzig, Surgical Pathology Update Course, "Molecular Prognosticators in Ovarian Cancer", June 2007

KCon-Fab Hereditary Cancer Meeting, Couran Cove Australia - "Pathology of Familial Ovarian Cancer" Aug 2007

BRCA Hereditary Breast and Ovarian Cancer Mtg, Montreal – “The Pathology of Familial Ovarian Cancer: New Developments” Oct 2007
 Univ of Sherbrooke, Sherbrooke QC - “Subclassification of ovarian cancer”, May 2008
 University of Minnesota Dept of Pathology Grand Rounds, “Subclassification of Ovarian Cancer Based on a Combination of Morphology and Molecular Abnormalities, Jan 2009
 British Columbia Cancer Agency, Gynecological Tumor Group Retreat, “Recent Advances in the Pathology of Ovarian Carcinoma”, Jan 2009
 University of Sao Paulo, Brazil, “Clinical Implications of Ovarian Cancer Subtype”, Gynecology rounds, April 2009
 Syrio-Lebanese Hospital, Sao Paulo, Brazil, “Pathological Subclassification of Ovarian Cancer Based on a Combination of Morphology and Molecular Abnormalities”, Gynecology rounds, April 2009
 University of Western Ontario, 4th Annual Gynecologic Oncology Update, V. Cecil Wright Lectureship, “Subclassification of Ovarian Cancer Based on a Combination of Morphology and Molecular Abnormalities”, May 2009
 “Developing the quality culture in anatomic pathology”, UBC Laboratory Quality Management Seminar, August 20, 2009
 “Subtypes of ovarian cancer”, British Columbia Society of Laboratory Science Congress, Oct 2, 2009
 “Defining new diagnostic markers in ovarian cancer” Gynecologic Oncology of Canada meeting, April 30, 2010
 “CIQC – Quality Assurance for Immunohistochemistry” National Society of Histotechnologists Education Days, May 29, 2010
 “Progress in IHC quality assurance” CAP-ACP/ciQc Diagnostic Immunohistochemistry Seminar, July 8 and 9, 2010, Montreal
 International Academy of Pathology, Oct 2010, Sao Paulo Brazil
 March 2011, Memorial University of Newfoundland
 May 2011, Saint John NB
 May 2011, Asia Pacific International Academy of Pathology. Taipei Taiwan
 May 2011, Pacific Northwest Society of Pathologists Meeting, Vancouver BC
 June 2011, CAP-ACP/ciQc Diagnostic Immunohistochemistry Seminar
 June 2011, Pathologists Assistant’s meeting, Vancouver BC
 June 2011, Canadian Association of Pathologists meeting, Vancouver BC
 Oct 2011, National Cancer Institute, Gynecologic Cancer Steering Committee 2011 Ovarian Cancer Clinical Trials Planning Meeting, Philadelphia PA
 May 2012, Phenopath Laboratories, 2 presentations: Ovarian surface epithelial carcinomas: Importance of subtype diagnosis, and Sex cord stromal tumors of the ovary
 Jan 2013. Grand rounds, Royal Inland Hospital, Kamloops BC. “Hereditary ovarian and endometrial cancer”
 Sept 2013. Gyne Path Rounds. Barts Health, London UK “Interesting case presentation”

(e) *Other Presentations*

(f) *Other*

Established the British Columbia Breast Cancer bank, a collection of >1000 breast cancer cases for use in cancer research, 1996

(g) *Conference Participation (Organizer, Keynote Speaker, etc.)*

Co-organizer, “Directions in Breast Cancer Research”, Vancouver Hospital, UBC site, February 24, 1996
 Participant, NCIC Workshop on tumor banking, April 1996
 Participant, NCI Workshop on terminology of endocrine tumors of the uterine cervix, May 1996

Moderator, Symposium on "Advances in Pathologic Diagnosis Affecting Treatment" Sept. 1997, CAP '97
Chair, Proffered Paper Session, Breast and Gynecologic Pathology, Sept. 1997, CAP '97
Presenter, Evening Gynecological Pathology Panel, March 8, 2001, USCAP
Co-Chair, Proffered Paper Session (Gynecologic Pathology) March 5, 2001, USCAP
Invited participant – NCI consensus conference of ovarian borderline tumors, August 27&28, 2003
Invited presenter, International Society of Gynecological Pathologists Specialty Conference at the
USCAP, March 7 2004
Short course presenter "Problems in the Evaluation of Surface Epithelial-Stromal Tumors of the Ovary: an
Update, USCAP, 2004-2007
Second Canadian Conference on Canadian Cancer Research, Keynote Address – "Molecular Advances
and Molecular Profiling", May 2004
Invited presenter - "Clinical and Pathological Variables Relevant to Patient Outcome in "Early" Ovarian
Cancer: analysis of a population-based series", Helene Harris Memorial Trust Ovarian Cancer Meeting,
Washington DC, May 2005
Organizing Committee and presenter. Molecular and Genetic Diagnostics of Human Cancer, N.N.
Blokhin Russian Cancer Research Center, Moscow, RU, Sept 2005
Scientific Program Convenor for Gynecological Pathology, International Academy of Pathology, Montreal
CA, Sept 2006
Invited presenter, International Academy of Pathology, Montreal CA, Sept 2006
Invited presenter, Gynecological Pathology Symposium in Honor of Professor Harold Fox, International
Gynecological Cancer Society Meeting, Santa Monica CA, Oct 2006
Invited presenter, Ovarian Tumor Board, International Gynecological Cancer Society Conference, Santa
Monica CA, Oct 2006
Moderator, International Society of Gynecological Pathology Specialty Conference, USCAP, March 2007
Invited Presenter, Surgical Pathology Update, sponsored by the University of Leipzig and M.D. Anderson
Cancer Center, Leipzig Germany, June 2007
Moderator, International Society of Gynecological Pathology Specialty Conference, USCAP, March 2008
Invited Presenter, International Society of Gynecological Pathology long course on Uterine Pathology,
International Academy of Pathology meeting, Athens Greece, Oct 2008
Invited Presenter, International Society of Gynecological Pathology Symposium on Ovarian Carcinoma,
International Gynecological Cancer Society meeting, Bangkok Thailand, Oct 2008
Invited Presenter, International Society of Gynecological Pathology Specialty Conference, USCAP, March
2009
Moderator, Proffered paper session on gynecological pathology, USCAP March 2009
Co-organizer, Diagnostic Immunohistochemistry meeting, April 2 and 3 2009, Vancouver BC
Invited Presenter (V. Cecil Wright Lectureship), University of Western Ontario, May 2009
Co-organizer and presenter, Joint BC-IPT and CAP meeting, "Quality in Pathology and
Immunohistochemistry", March 15, 2010
Co-organizer, First international symposium on ovarian clear cell carcinoma, June 24, 2010, Vancouver
Co-organizer, 2nd annual CAP-ACP/cIQc Diagnostic Immunohistochemistry Seminar, July 8 and 9, 2010,
Montreal
Co-organizer, 3rd annual CAP-ACP/cIQc Diagnostic Immunohistochemistry Seminar, June 2 and 3, 2011,
Vancouver
Keynote speaker (Peter Davies Lecture), Banff Pathology Conference, Sept 2011, "Sex cord-stromal
tumors of the ovary"
Invited presenter, Gynecological Pathology Symposium in honor of Dr. Vera Abeler, Norwegian Radium
Hospital, Oslo Norway, May 2012, "Molecular correlates of ovarian carcinoma subtypes"
British Society for Gynecological Pathology annual meeting, June 2012, "Endometrial cancer:
controversies in histopathological assessment of grade and tumor cell type"
Invited presenter, British Gynecological Cancer Society annual meeting, July 2012, "Ovarian carcinoma
subtypes: diagnosis, differential diagnosis, and clinical relevance, a success story!"
Invited presenter, Xinjiang Pathology Association, Urumqi China; 3 lectures, on ovarian carcinoma,
endometrial carcinoma, and sex-cord stromal tumors of ovary Sept 2012
Invited presenter, National Society of Histotechnologists, Vancouver, Sept 2012, "Use of tissue
microarrays for quality assurance in immunohistochemistry"

Invited presenter, International Academy of Pathology, Cape Town, South Africa, Oct 2012 "Early serous carcinoma of the fallopian tube"

Invited presenter, DA Boyes Gynecological Cancer Society, Vancouver, Oct 2012, "Identifying Lynch Syndrome in women with endometrial carcinoma"

Co-organizer, cIQC Diagnostic Immunohistochemistry Conference, May 2013, Toronto

Invited Presenter, Gynecological Oncology Society of Canada, Toronto, May 2013, "The role of pathology in identification of hereditary cancer susceptibility syndromes"

Invited Presenter, Nordic Gynecological Pathology Society, Stockholm, April 2013, "Importance of accurate subclassification of ovarian cancer"

Participant, Panel discussion on endometrial cancer grading and staging, USCAP, March 2014 San Diego CA

Invited presenter, Canadian Ovarian Cancer Conference, June 2014, Victoria BC

Co-organizer and presenter, cIQC Diagnostic Immunohistochemistry Conference, June 2014, St. John's NF

Invited Presenter, Diagnostic Immunohistochemistry Quality Assurance Summit, August 2014, London UK

Invited Presenter, WHO Classification of Tumours of the Ovary Fallopian Tube and Peritoneum, International Gynecological Cancer Society Conference, November 2014, Melbourne

Invited Presenter, ARID1a mutations in Ovarian Clear Cell Carcinoma, International Gynecological Cancer Society Conference, November 2014, Melbourne

Invited Presenter, Progress in Endometrial Cancer Pathology and Pathogenesis, International Gynecological Cancer Society Conference, November 2014, Melbourne

Invited Presenter, Pathology of the Fallopian Tube; Then and Now, International Gynecological Cancer Society Conference, November 2014, Melbourne

Invited Presenter, Quality assurance in immunohistochemistry, CIQC, Canadian Partnership Against Cancer World Cancer Day Symposium, February 2015, Toronto

10. SERVICE TO THE UNIVERSITY

(a) *Memberships on committees, including offices held and dates*

Chairman, Molecular Pathology Committee, UBC, Department of Pathology, 1992-1996

Search Committee for Head of Laboratory Medicine, VHHSC, 1993-1994

Curriculum Sub-committee to review Path 401A and Path 401B, 1993

Academic Advisor, Pathology Residency Program, 1994-present

Residency Training Committee member, 1992-present

Anatomic Pathology Site Supervisor for residency, 1992-2001

Member, Faculty Executive, 1993-present

GI/Nutrition Block Committee of P2P2, 1996-2005

Search Committee for Assistant Dean Faculty Educational Development, 1998

VHHSC Laboratory Medicine Advisory Committee - 1999-2001

VHHSC Physicians Advisory Group for the Patient Care Information System, 1999-2001

VHHSC Division Heads and Quality Advisory Committee, 1999-2001

MD Undergraduate Curriculum Enhancement Committee, 2002-present

Peer Evaluation of Teaching Effectiveness Committee, 2002-present

Anatomic Pathology Residency Program Director, 2003-2009

Anatomic Pathology Residency, Site Supervisor for VGH, 2009-present

(b) *Other service, including dates*

Development of Flow cytometry as adjunct to existing cytology service at UBC site (1993-94)

Coordinator Resident Molecular Pathology elective (1994-present)

Resident Teaching (1991-present)

Director of Immunohistochemistry Laboratory, Vancouver General Hospital (2001-2009)

Member of Anatomic Pathology Search Committee (2002)

11. **SERVICE TO THE COMMUNITY**

(a) *Memberships on scholarly committees, including offices held and dates*

Alpha Omega Alpha Honor Medical Society
 International Society of Gynecological Pathology
 Canadian Association of Pathologists
 Fellow of the Royal College of Physicians (Canada)
 Canadian Society of Cytology

(b) *Memberships on other societies, including offices held and dates*

Executive, International Society of Gynecological Pathologists, 2006-2009
 Co-chair, committee to revise the WHO classification of ovarian tumors, 2011-present

(c) *Memberships on scholarly committees, including offices held and dates*

Advisory Committee for DNA Diagnostic Laboratory at BCCH, 1994-1995
 Professional Association of Pathologists Steering Committee for contract negotiations, 1994
 Advisory Committee for BC Breast Cancer Bank, 1996-1999

(d) *Memberships on other committees, including offices held and dates*

Member of New Investigators Committee, British Columbia Health Research Foundation, 1997-2001
 Member of Review Panel B, NCIC, 2000-2002
 Member of Examination Board, Anatomical Pathology, Royal College of Physicians and Surgeons of Canada, 2002-2006
 Member of the Medical Advisory Committee of Breast Cancer Foundation, BC-Yukon Division, 2003-present
 Member of Review Panel J1, NCIC, 2009-2010

(e) *Editorships (list journal and dates)*

Editorial Board, International Journal of Gynecological Pathology, 1997-2012
 Editorial Board, Gynecologic Oncology, 2005-2008
 Editorial Board, American Journal of Surgical Pathology, 2008-present
 Editorial Board, Histopathology, 2012-present

(f) *Reviewer (journal, agency, etc. including dates)*

Medical Research Council of Canada, 1997-2001
 British Columbia Health Research Foundation, 1997-2001
 Arch Pathol Lab Med, 1997-present
 Canadian Breast Cancer Foundation, 1999-present
 Gynecologic Oncology, 1999-present
 National Cancer Institute of Canada - 2001-2003
 Pathology, 2001-present
 Am J Obstet Gynecol, 2002-present
 Journal of the National Cancer Institute, 2002-present
 MMSFHR Research Trainee Clinical Research Evaluation Committee, 2009-2011
 Vancouver Coastal Health Research Institute, Team Grant competition, 2011

(g) *External examiner (indicate universities and dates)*

Royal College of Physicians and Surgeons, Anatomic Pathology, 2002-2007

(h) *Consultant (indicate organization and dates)*

Member, US-Canadian Mesothelioma Reference Panel, 1992-2001
Alternate member of Breast and Lung panels of Canadian Reference Centre for Cancer Pathology (1997-2001)
Member of Gynecologic pathology panel of Canadian Reference Centre for Cancer Pathology (1997-2001)

(i) *Other service to the community*

12. AWARDS AND DISTINCTIONS

(a) *Awards for Teaching (indicate name of award, awarding organizations, date)*

Mel Bernstein Award for Resident Teaching, 1994
Roberta Miller Award for "Outstanding Professional Role Model", Pathology and Lab Medicine Residency Program, 1998

(b) *Awards for Scholarship (indicate name of award, awarding organizations, date)*

- 1 "In It For Life" Scientist Award, Vancouver Coastal Health Research Institute, 2004
- 2 Killam Faculty Research Award for University of British Columbia, 2014

(c) *Awards for Service (indicate name of award, awarding organizations, date)*

Dept of Pathology Award for Excellence in Clinical Service, 2003
Bringing Clinical Renown to VA award, Vancouver Acute, VCH, 2009

(d) *Other Awards*

Dept of Pathology Award for Excellence in Research and Discovery, 2009

13. OTHER RELEVANT INFORMATION (Maximum One Page)

THE UNIVERSITY OF BRITISH COLUMBIA
Publications Record

SURNAME: GILKS

FIRST NAME: CYRIL
MIDDLE NAME(S): BlakeInitials
Date: January 2006**1. REFEREED PUBLICATIONS***(a) Journals*

- 1 Gilks CB and Clement PB. Colo-ovarian fistula: a report of two cases. *Obstetrics and Gynecology* 69:533-537 (1987).
- 2 Gilks CB and Clement PB. Inflammatory pseudo tumor of the uterus. *Int J Gyn Path* 6:275-286 (1987).
- 3 Gilks CB and Churg A. Aluminum induced pulmonary fibrosis: do fibers play a role?. *Am Rev Resp Dis* 136:176-179 (1987).
- 4 Gilks CB, Hegedus C, Freeman H, Fratkin L, and Churg A. Malignant peritoneal mesothelioma after remote abdominal radiation. *Cancer* 61:2019-2021 (1988).
- 5 De Negri J, Gilks CB, Peterson J, Atkin M, and Lafleur L. A novel T-cell activation antigen present on allo-specific primed lymphocytes and defined by the monoclonal antibody VG01. *Transplantation* 45:978-984 (1988).
- 6 Gilks CB, Wright J, and Churg A. Effects of cigarette smoke on tissue uptake and retention of iron oxide in the guinea pig. *Am Rev Resp Dis* 137:1382-1384 (1988).
- 7 Hobson J, Gilks CB, Wright J, and Churg A. Cigarette smoke directly enhances asbestos fiber penetration and epithelial proliferative activity in rat tracheal explants. *J.N.C.I.* 80:518-521 (1988).
- 8 Gilks CB and Tavasolli F. Coexistence of intracytoplasmic lumens and membrane-bound vesicles in an invasive carcinoma arising in a cystosarcoma phyllodes. *Ultrastructural Pathology* 12:631-642 (1988).
- 9 Gordon PB, and Gilks CB. Sonographic appearance of normal intramammary lymph nodes. *J Ultrasound Med* 7:545-548 (1988).
- 10 Gilks CB, Reid PE, Clement PB, and Owen DA. Simple procedure for assessing relative quantities of neutral and acidic mucin glycoproteins: its use in assessing cyclical changes in cervical mucins. *J Clin Path* 41:1021-1024 (1988).
- 11 Gilks CB, Reid PE, Clement PB, and Owen DA. Changes in composition of cervical mucin glycoproteins during the normal menstrual cycle. *Fertil Steril* 51:286-291 (1989).
- 12 Churg A, Wright JL, Gilks B, and DePaoli L. Rapid short-term clearance of chrysotile compound with amosite asbestos in the guinea pig. *Am Rev Respir Dis* 1139-885-890 (1989).
- 13 Gilks CB, Clement PB, and Wood WS. Trichoblastic fibroma: clinicopathologic study of three cases. *Am J Dermatopathol* 11:397-402 (1989).
- 14 Becker CD, Gilks CB, and Burhenne HJ. Biological effects of biliary shock wave lithotripsy in swine. *Invest Radiol* 24:366-370 (1989).
- 15 Gilks CB, Young RH, Aguirre P, DeLellis RA, and Scully RE. Adenoma Malignum (minimal deviation adenocarcinoma) of the uterine cervix. A clinicopathological and immunohistochemical analysis of 26 cases. *Am J Surg Pathol* 13:717-729 (1989).
- 16 Gilks CB, Bell DA, and Scully RE. Serous psammocarcinoma of the ovary and peritoneum. *Int J Gynecol Pathol* 9:110-121 (1990).
- 17 Young RH, Gilks CB, and Scully RE. Mucinous tumors of the appendix associated with mucinous tumors of the ovary: a clinicopathological analysis of 22 cases. *Am J Surg Pathol* 15:415-29 (1991).
- 18 Gilks CB, and Ellison DJ. Intratumoral T lymphocytes from small cleaved follicular center cell lymphomas show unrestricted T cell receptor-chain variable region gene usage. *Am J Pathol* 139:25-28 (1991).
- 19 Gilks CB, Ho VC, Gascoyne RD, and Ellison DJ. T-cell receptor variable region gene expression in cutaneous T-cell lymphomas. *J Cutan Pathol* 19:21-26 (1992).
- 20 Gilks CB and Clement PB. Papillary serous carcinoma of the uterine cervix: a report of three cases. *Modern*

- Pathol 5:426-431 (1992).
- 21 Gilks CB, Bear SE, Grimes HL and Tschlis PN. Progression of interleukin-2 (IL-2) dependent rat T cell lymphoma cell lines to IL-2 independent growth following activation of a gene (Gfi-1) encoding a novel zinc finger protein. *Mol Cell Biol* 13:1759-1768 (1993).
 - 22 Porter SD, and Gilks CB. Genomic imprinting: a proposed explanation for the different behaviours of testicular and ovarian germ cell tumors. *Med Hypothesis* 41:37-41 (1993).
 - 23 Donn W, Rebbeck P, Wilson C, and Gilks CB. Idiopathic granulomatous mastitis; a report of three cases and review of the literature. *Arch Pathol Lab Med* 118:822-825 (1994).
 - 24 Huntsman D, Clement PB, Gilks CB, and Sculley RE. Small cell carcinoma of the endometrium. *Am J Surg Pathol*, 18:364-375 (1994).
 - 25 Tschlis PN, Makris A, Patriotis C, Gilks CB, and Bear SE. Progression of retrovirus induced rodent T cell lymphomas and regulation of T cell growth; an insertional mutagenesis based genetic strategy. *Proceedings of the 128th meeting of the Society for General Microbiology*, Cambridge University Press (1994).
 - 26 Thurley CA, Kwan WC, Freeman H, and Gilks CB. T cell receptor gene expression and genotypes in celiac disease. *Pathobiol* 62:311-318 (1994).
 - 27 Awadh N, Ronco JJ, Bernstein V, Gilks B, Wilcox P. Spontaneous pulmonary haemorrhage following thrombolytic therapy for acute myocardial infarction. *Chest* 106:1622,1624 (1994).
 - 28 Gourlay W, Chan V, and Gilks CB. Screening for urothelial malignancies by cytology and flow cytometry in a community urologic practice: A prospective study. *Mod Pathol*, 8:394-397 (1995).
 - 29 Bell DW, Taguchi T, Jenkins NA, Gilbert DJ, Copeland NG, Gilks CB, Zweidler-McKay P, Grimes HL, Tschlis PN, and Testa JR. Chromosomal localization of a gene, GFI-1, encoding a novel zinc finger protein reveals a new syntenic region between man and rodents. *Cell Genet Cytogenet* 70:263-267 (1995).
 - 30 Churg A, Keeling B, Gilks CB, Porter SD and Olive P. Mesothelial and tracheal epithelial cells show equal sensitivity to oxidant injury: single cell analysis by the comet assay. *Am J Physiol* 268:L832-838 (1995).
 - 31 Gilks CB, Porter SD, Barker C, Tschlis PN, and Gout PW. Prolactin (PRL) induced expression of a novel gene, Gfi-1, in PRL-dependent rat Nb2 node lymphoma cells: constitutive expression in PRL-independent cells. *Endocrinology* 136:1805-1808 (1995).
 - 32 Gilks CB, Young RH, Clement PB, Hart WR, Scully RE. Adenomyomas of the uterine cervix of endocervical type. *Mod Pathol* 9:220-224 (1996).
 - 33 Lesack D, Wabab I, Gilks CB. Radiation induced atypia of endocervical epithelium: a histological, immunohistochemical and cytometric study. *Int J Gynecol Pathol* 15:242-247 (1996).
 - 34 Thurley CA, Sahl B, Kwan WC, Freeman H, Gilks CB. Analysis of germline and expressed T cell receptor variable region genes in Crohn's disease. *Pathol Res Prac* 192:1022-1030 (1996).
 - 35 Grimes HL, Gilks CB, Chan TO, Porter SD, Tschlis PN. The Gfi-1 protooncogene represses Bax expression and inhibits death of primary explanted thymocytes. *Proc Natl Acad Sci* 93:14569-14573 (1996).
 - 36 Gilks CB, Young RH, Gersell DJ, Clement PB. Large cell neuroendocrine carcinomas of the uterine cervix. *Am J Surg Pathol*, 21:905-914 (1997).
 - 37 Albores-Saavedra J, Gersell D, Gilks CB, et al. Terminology of endocrine tumors of the uterine cervix: results of a workshop sponsored by the College of American Pathologists and the National Cancer Institute. *Arch Pathol Lab Med* 121:34-39 (1997).
 - 38 Gilks CB, Young RH, Gersell DJ, Clement PB. Large cell neuroendocrine carcinomas of the uterine cervix. *Am J Surg Pathol*, 21:905-914 (1997).
 - 39 Vogrinic G, O'Connell JXO, Gilks CB. Giant cell tumors of tendon sheath are a polyclonal cellular proliferation. *Human Pathol* 28:815-819 (1997).
 - 40 Zhou C, Gilks CB, Hayes M, Clement PB. Papillary serous carcinoma of the uterine cervix: a clinicopathological study of 17 cases. *Am J Surg Pathol* 22:113-120 (1998).
 - 41 Gilks CB, Price K, Wright JL, Churg A. Antioxidant gene expression in rat lung after exposure to cigarette smoke. *Am J Pathol* 152:269-278 (1998).
 - 42 Wehrli BM, Krajewski S, Gascoyne RD, Reed JC, Gilks CB. Immunohistochemical analysis of Bcl-2, Bax, Mcl-1 and Bcl-X expression in ovarian surface epithelial tumors. *Int J Gynecol Pathol* 17:255-260 (1998).
 - 43 Dai J, Gilks CB, Price K, Churg A. Mineral dusts induce epithelial fibrogenic mediators and matrix components without a requirement for airspace inflammatory cells. *Am J Resp Crit Care Med* 158:1907-1913 (1998).
 - 44 Gilks CB. Ovarian surface epithelial tumors of borderline malignancy. *Annals of Contemporary Diagnostic Pathology*, 2:47-54 (1998).
 - 45 Lim P, Aquino-Parsons CF, Wong F, Dupuis B, Phillips D, Zhou C, Gilks CB. Low Risk Stage 1 Endometrial

- Carcinoma: assessment of a treatment policy based on tumor ploidy and identification of additional prognostic indicators. *Gyne Onc* 73:191-195 (1999).
- 46 Porter SD, Hu J, Gilks CB. A distal upstream tryosinase S/MAR containing sequence has regulatory properties specific to subsets of melanocytes. *Dev Genetics* 25:40-48 (1999).
 - 47 Crawford D, Nimmo M, Clement PD, Thomson T, Benedet JL, Miller D, Gilks CB. Prognostic factors in Paget's disease of the vulva: a study of 21 cases. *Int J Gynecol Pathol* 18:351-359 (1999).
 - 48 Dhami R, Zay K, Gilks CB, Porter SD, Wright JL, Churg A. Pulmonary epithelial expression of human alpha-1-antitrypsin in transgenic mice results in delivery of alpha-1-antitrypsin protein to the interstitium. *J Mol Med* 77:377-385 (1999)
 - 49 Wong ETL, Jenne DE, Porter SD, Gilks CB. Changes in chromatin organization at the neutrophil elastase locus associated with myeloid cell differentiation. *Blood* 94:3730-6 (1999)
 - 50 Churg A, Gilks B, Dai J. Fine and ultrafine titanium dioxide induce a different pattern of fibrogenic mediator expression in rat tracheal explants. *Am J Physiol* 277:L975-982 (1999).
 - 51 Wright JL, Dai J, Zay K, Price K, Gilks CB, Churg A. Effects of cigarette smoke on nitric oxide synthase expression in the rat lung. *Lab Invest* 79:795-983 (1999).
 - 52 Dhami R, Gilks B, Xie C, Zay K, Wright J, Churg A. Cigarette smoke-induced connective tissue breakdown is mediated acutely by neutrophils and prevented by alpha-1-antitrypsin. *Am J Resp Cell Mol Biol* 22:244-252 (2000).
 - 53 Gilks CB, Clement PB, Hart WR, Young RH. Uterine adenomyomas excluding atypical polypoid adenomyomas and adenomyomas of endocervical type. *Int J Gynecol Pathol*, 19:195-205 (2000).
 - 54 Irving JA, McFarland DF, Stuart DS, Gilks CB. Mitotic arrest of endometrial epithelium following paclitaxel therapy for breast cancer. *Int J Gynecol Pathol* 19:395-397 (2000).
 - 55 Churg A, Colby TV, Cagle P, Corson J, Gibbs AR, Gilks B, Grimes M, Hammar S, Roggli V, Travis WD. The separation of benign and malignant mesothelial proliferations. *Am J Surg Pathol* 24:1183-1200 (2000).
 - 56 Cox M, Gilks B. Assessment of histopathological features to allow distinction between healed or quiescent temporal arteritis and atherosclerosis. *Pathology* 33:163-166 (2001).
 - 57 Lim P, Al-Kushi A, Gilks CB, Wong F, Aquino-Parsons C. Papillary serous carcinoma of the endometrium: effect of adjuvant whole abdominal radiotherapy and pathologic parameters on outcome. *Cancer* 91:752-757 (2001).
 - 58 Al-Sheikh A, Mohamedali Z, Jones E, Masterson J, Gilks CB. Comparison of WHO classification and Cytokeratin 20 expression in predicting behaviour of low-grade papillary urothelial tumors. *Mod Pathol* 14:267-272 (2001).
 - 59 Irving J, Gilks CB. Diagnosis of endometrial hyperplasia and low-grade endometrial adenocarcinoma: a review for the practicing pathologist. *Annals of Contemporary Diagnostic Pathology* 4:15-24 (2001).
 - 60 Parker R, Lanvin D, Gilks B, Miller D. Spontaneous regression of stage IV clear cell carcinoma of the endometrium in a patient with essential thrombocytosis. *Gynecol Oncol* 82:395-399 (2001).
 - 61 Taylor E, Gilks B, Lanvin D. Amyloidosis of the uterine cervix presenting as postmenopausal bleeding. *Obstet Gynecol* 98:966-968 (2001).
 - 62 Al-Ghamdi A, Freedman D, Miller D, Poh C, Rosin M, Zhang L, Gilks CB. Invasive vulvar squamous cell carcinoma in young women: a clinicopathologic study of 21 cases. *Gynecol Oncol* 84:94-101 (2002).
 - 63 Yue J, Miller D, Gilks CB. Advanced stage serous borderline tumors of the ovary: a clinicopathological study of 49 cases. *Int J Gynecol Pathol* 22:29-36 (2002).
 - 64 Poon KS, Gilks CB, Masterson JS. Metastatic Crohn's disease involving the genitalia. *J Urol* 167:2541-2542 (2002).
 - 65 Parker R, Cupples J, Lesack D, Grant D, Huntsman D, Gilks CB. Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. *Am J Clin Path* 117:723-728 (2002).
 - 66 Al-Kushi M, Lim P, Aquino-Parsons C, Gilks CB. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid carcinoma but not papillary serous carcinoma of the endometrium. *Mod Pathol* 15:365-371 (2002).
 - 67 Irving J, Dupuis B, Wang L, Gilks CB. Cyclical expression of the DNA mismatch repair enzyme hMLH1 in normal endometrium. *Fertil Steril* 78:195-196 (2002).
 - 68 Hsu F, Nielsen TO, Alkushi A, Dupuis B, Huntsman D, Lui C-L, van de Rijn M, Gilks CB. Multiple tumor microarrays are an effective quality assurance tool for diagnostic immunohistochemistry laboratories. *Mod Pathol* 15:1374-1380 (2002).
 - 69 Liu CL, Prapong W, Natkuman Y, Alizadeh A, Montgomery K, Gilks CB, van de Rijn M. Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. *Am J Pathol* 161:1557-1564 (2002).

- 70 Al-Kushi A, Irving J, Hsu F, Dupuis B, Lui C-L, van de Rijn M, Gilks CB. Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray. *Virchows Archiv.* 442:271-277 (2003)
- 71 Nielsen TO, Hsu FD, O'Connell JX, Gilks CB, West RB, Liu CL, Botstein D, Brown P, van de Rijn M. Tissue microarray analysis of novel synovial sarcoma immunohistochemical markers. *Am J Pathol* 2003;163(4):1449-1456.
- 72 Makretsov N, Gilks B, Coldman A, Hayes M and Huntsman D. Tissue microarray analysis of neuroendocrine differentiation and its prognostic significance in breast cancer. *Human Pathol*, 2003, Oct; 34(10): 1001-1008.
- 74 Hughes-Davies L, Huntsman DG, Ruas M, Fuks F, Bye J, Chin S-F, Milner J, Brown LA, Irving JA, Hsu F, Gilks CB, Nielsen TO, Schulzer M, Chia S, Ragaz J, Longacre TA, Cahn A, Leversha M, Linger L, Cattaneo E, Theillet C, Jordanova ES, Schuurung E, Yu D, Aparicio S, Venkitaraman A, Ponder B, Doherty A, Bentley D, Ponting C, Caldas C, and Kouzarides T. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. *Cell* 2003;115:523-535.
- 75 Linn SC, West RB, Pollack JR, Zhu S, Hernandez-Boussard T, Nielsen TO, Rubin BP, Patel R, Goldblum JR, Siegmund D, Botstein D, Brown PO, Gilks CB, van de Rijn M. Gene Expression Patterns and Gene Copy Number Changes in Dermatofibrosarcoma Protuberans. *Am J Pathol*, 2003; 163:2383-2395.
- 76 Nielsen TO, Cheang M, Kucab JE, Hsu FD, Ragaz J, Gilks CB, Makretsov N, Bajdik, CD, Brookes C, Neckers LM, Huntsman DG, Dunn SE. Co-expression of the insulin-like growth factor-1 receptor (IGF-1R) and urokinase plasminogen activator (uPA) in breast cancer is associated with poor survival: Potential for intervention with 17 allylamino geldanamycin (17AAG). *Cancer Res*, 2004; 64:286-291.
- 77 Alkushi A, Lim P, Coldman A, Huntsman D, Miller D, Gilks CB. Interpretation of p53 immunohistochemical staining in endometrial carcinoma: establishing a clinically relevant cut-off. *Int J Gynecol Pathol*, 2004; 23:129-137.
- 78 Somasiri A, Nielsen J, Makretsov N, Gilks CB, Huntsman D, Gelmon KA, Kershaw DB, McNagny KM, Roskelley CD. Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression. *Cancer Res.* 2004 Aug 1;64(15):5068-73.
- 79 van de Rijn M, C.B. Gilks. Applications of Microarrays in Diagnostic Pathology. *Histopathology*, 2004; 44:97-108.
- 80 Doan LL, Porter SD, Duan Z, Jay CM, Flubacher MM, Tschlis PN, Horwitz M, Gilks CB, Grimes LH. Targetted transcriptional repression of Gfi1 and Gfi1B in lymphoid cells. *Nucleic Acids Res.* 2004 May 6;32(8):2508-19.
- 81 Au N, Cheang M, Huntsman D, Yorida E, Coldman A, Elliott M, Bebb G, Flint J, English J, Gilks CB, Grimes LH. Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers. *J Pathol.* 2004 Sep;204(1):101-9.
- 82 Au N, Gown A, Cheang M, Huntsman D, Yorida E, Elliott M, Flint J, English J, Gilks CB, Grimes LH. P63 expression in lung carcinoma: a tissue microarray study of 408 cases. *Appl Immunohistochem Mol Morphol.* 2004 Sep;12(3):240-7.
- 83 Parker RL, Clement PB, Chercover DJ, Sornarajah T, Gilks CB. Early recurrence of ovarian serous borderline tumor as high-grade carcinoma: a report of two cases. *Int J Gynecol Pathol.* 2004 Jul;23(3):265-72.
- 84 Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hernandez-Boussard T, Cowan D, Dressler L, Livasy C, Aksien LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M and Perou CM. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. *Clin Cancer Res.* 2004 Aug 15;10(16):5367-74.
- 85 Woo MMM, Gilks CB, Verhage HG, Longacre TA, Leung PCK and Auersperg N. Oviductal Glycoprotein (OGP), a New Differentiation-based Indicator Present in Early Ovarian Epithelial Neoplasia and Cortical Inclusion Cysts. *Gynecol Oncol*, 2004; 93:315-319.
- 86 Dabiri SH, Huntsman D, Makretsov N, Cheang M, Gilks CB, Bajdik C, Gelmon K, Chia S, Hayes MM. The Presence of Stromal Mast Cells Identifies a Subset of Invasive Breast Cancers with a Favourable Prognosis. *Mod Pathol*, 2004; 17:690-695.
- 87 Makretsov NA, Huntsman DG, Nielsen TO, Yorida E, Peacock M, Cheang MC, Dunn SE, Hayes M, van de Rijn M, Bajdik C, Gilks CB. Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma. *Clin Cancer Res.* 2004 Sep 15;10(18 Pt 1):6143-51.
- 88 Gilks CB. Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data. *Int J Gynecol Pathol.* 2004 Jul;23(3):200-5. Review.
- 89 Kazanjian A, Wallis D, Au N, Nigam R, Venken KJ, Cagle PT, Dickey BF, Bellen HJ, Gilks CB, Grimes HL. Growth factor independence-1 is expressed in primary human neuroendocrine lung carcinomas and mediates the differentiation of murine pulmonary neuroendocrine cells. *Cancer Res.* 2004 Oct 1;64(19):6874-82.

- 90 Ronnett B, Kajdacsy-Balla A, Gilks CB, Merino MJ, Silva E, Werness BA, Young RH. Mucinous borderline ovarian tumors: points of general agreement and persistent controversies regarding nomenclature, diagnostic criteria, and behavior. *Hum Pathol*. 2004 Aug;35(8):949-60.
- 91 Woo MMM, Alkushi A, Verhage HG, Leung PCK, Gilks CB, Auersperg N. Gain of OGP, an estrogen-regulated oviduct-specific glycoprotein, is associated with the development of endometrial hyperplasia and endometrial cancer. *Clin Cancer Res*. 2004 Dec 1;10(23):7958-64.
- 92 Stone JE, Parker R, Gilks CB, Stanbridge EJ, Liao SY, Aquino-Parsons C. Intratumoral oxygenation of invasive squamous cell carcinoma of the vulva is not correlated with regional lymph node metastasis. *Eur J Gynaecol Oncol*. 2005;26(1):31-5.
- 93 Lee CH, Xue H, Sutcliffe M, Gout PW, Huntsman DG, Miller DM, Gilks CB, Wang YZ. Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. *Gynecol Oncol*. 2005 Jan;96(1):48-55.
- 94 Alkushi A, Abdul-Rahman ZH, Lim P, Schulzer M, Coldman A, Kalloger SE, Miller D, Gilks CB. Description of a novel system for grading of endometrial carcinoma and comparison with existing grading systems. *Am J Surg Pathol*. 2005 Mar;29(3):295-304.
- 95 Gilks CB, Vanderhyden BC, Zhu S, van de Rijn M, Longacre TA. Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. *Gynecol Oncol*. 2005 Mar;96(3):684-94.
- 96 Elishaev E, Gilks CB, Miller D, Srodon M, Kurman RJ, Ronnett BM. Synchronous and metachronous endocervical and ovarian neoplasms: evidence supporting interpretation of the ovarian neoplasms as metastatic endocervical adenocarcinomas simulating primary ovarian surface epithelial neoplasms. *Am J Surg Pathol*. 2005 Mar;29(3):281-94.
- 97 Lee CH, Huntsman DG, Cheang MC, Parker RL, Brown L, Hoskins P, Miller D, Gilks CB. Assessment of Her-1, Her-2, and Her-3 Expression and Her-2 Amplification in Advanced Stage Ovarian Carcinoma. *Int J Gynecol Pathol*. 2005 Apr;24(2):147-152.
- 98 Wiseman SM, Makretsov N, Nielsen TO, Gilks B, Yorida E, Cheang M, Turbin D, Gelmon K, Huntsman DG. Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. *Cancer*. 2005 May 1;103(9):1770-7.
- 99 Ludwick C, Gilks CB, Miller D, Yaziji H, Clement PB. Aggressive behavior of stage I ovarian mucinous tumors lacking extensive infiltrative invasion: a report of four cases and review of the literature. *Int J Gynecol Pathol*. 2005 Jul;24(3):205-17.
- 100 Prentice LM, Shadeo A, Lestou VS, Miller MA, Deleeuw RJ, Makretsov N, Turbin D, Brown LA, Macpherson N, Yorida E, Cheang MC, Bentley J, Chia S, Nielsen TO, Gilks CB, Lam W, Huntsman DG. NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis. *Oncogene*. 2005 Jul 18; [Epub ahead of print]
- 101 Alkushi A, Gilks CB. Description of a novel system for grading of endometrial carcinoma and comparison with existing grading systems. *Am J Surg Pathol*. 2005 Aug;29(8):1116-7.
- 102 Martin JD, Gilks B, Lim P. Papillary serous carcinoma--a less radio-sensitive subtype of endometrial cancer. *Gynecol Oncol*. 2005 Aug;98(2):299-303.
- 103 Kucab JE, Lee C, Chen CS, Zhu J, Gilks CB, Cheang M, Huntsman D, Yorida E, Emerman J, Pollak M, Dunn SE. Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. *Breast Cancer Res*. 2005;7(5):R796-807. Epub 2005 Aug 1.
- 104 Turbin DA, Cheang MC, Bajdik CD, Gelmon KA, Yorida E, De Luca A, Nielsen TO, Huntsman DG, Gilks CB. MDM2 protein expression is a negative prognostic marker in breast carcinoma. *Mod Pathol*. 2005 Sep 2; [Epub ahead of print]
- 105 Brown LA, Irving J, Parker R, Kim H, Press JZ, Longacre TA, Chia S, Magliocco A, Makretsov N, Gilks B, Pollack J, Huntsman D. Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas. *Gynecol Oncol*. 2005 Oct 14; [Epub ahead of print]
- 106 Tse GM, Tan PH, Ma TK, Gilks CB, Poon CS, Law BK. CD44s is useful in the differentiation of benign and malignant papillary lesions of the breast. *J Clin Pathol*. 2005 Nov;58(11):1185-8.
- 107 Wang Y, Xue H, Cutz JC, Bayani J, Mawji NR, Chen WG, Goetz LJ, Hayward SW, Sadar MD, Gilks CB, Gout PW, Squire JA, Cunha GR, Wang YZ. An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. *Lab Invest*. 2005 Nov;85(11):1392-404.
- 108 West, R.B. et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. *Proc Natl Acad Sci U S A*, 2006. 103(3):p. 690-5.

- 109 Ota T, Choi KB, Gilks CB, Leung PC, Auersperg N. Cell type- and stage-specific changes in HOXA7 protein expression in human ovarian folliculogenesis: possible role of GDF-9. *Differentiation*. 2006 Feb;74(1):1-10.
- 110 Wu J, Lee C, Yokom D, Jiang H, Cheang MC, Yorida E, Turbin D, Berquin IM, Mertens PR, Iftner T, Gilks CB, Dunn SEDisruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. *Cancer Res*. 2006 May 1;66(9):4872-9.
- 111 Tse GM, Tan PH, Lui PC, Gilks B, Poon CS, Ma TK, Law BK, Lam WW. The role of immunohistochemistry for smooth muscle actin, p63, CD10 and CK 14 in the differential diagnosis of papillary lesions of the breast. *J Clin Pathol*. 2006 May 12; [Epub ahead of print].
- 112 Wiseman SM, Masoudi H, Niblock P, Turbin D, Rajput A, Hay J, Filipenko D, Huntsman D, Gilks B. Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma. *Am J Surg*. 2006 May;191(5):581-7.
- 113 Hayes DN, Monti S, Pamigiani G, et al. Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. *J Clin Oncol* 2006;24:5079-90.
- 114 Mao T-L, Hsu C-Y, Yen MJ, et al. Expression of Rsf-1, a chromatin remodeling gene, in ovarian and breast carcinoma. *Hum Pathol*, 2006;37:1169-1175.
- 115 Masoudi H, Van Niekerk DJ, Gilks CB, Cheang M, Bilek K, Fischer U, Ehlen T, Miller D, Horn LC. Loss of p16 INK4 expression in invasive squamous cell carcinoma of the uterine cervix is an adverse prognostic marker. *Histopathology* 2006;49:542-5.
- 116 Choi JH, Gilks CB, Auersperg N, Leung PC. Immunolocalization of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and type I GnRH receptor during follicular development in the human ovary. *J Clin Endocrinol Metab* 2006;91:4562-70.
- 117 Makretsov NA, Hayes M, Carter BA, Dabiri S, Gilks CB, Huntsman DG. Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade. *Mod Pathol* 2007;20:84-89.
- 118 Cheang MC, Treaba DO, Speers CH, et al. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. *J Clin Oncol* 2006, Dec 20;24(36):5637-44. Epub 2006 Nov 20.
- 119 Cupp JS, Miller MA, Montgomery KD, Nielsen TO, O'Connell JX, Huntsman D, van de Rijn M, Gilks CB, West RB. Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides. *Am J Surg Pathol*. 2007 Jun;31(6):970-6.
- 120 Wiseman SM, Griffith OL, Deen S, Rajput A, Masoudi H, Gilks B, Goldstein L, Gown A, Jones SJ. Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma. *Arch Surg*. 2007 Aug;142(8):717-27.
- 121 Wiseman SM, Masoudi H, Niblock P, Turbin D, Rajput A, Hay J, Bugis S, Filipenko D, Huntsman D, Gilks B. Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. *Ann Surg Oncol*. 2007 Feb;14(2):719-29.
- 122 Ionescu DN, Treaba D, Gilks CB, Leung S, Renouf D, Laskin J, Wood-Baker R, Gown AM. Nonsmall cell lung carcinoma with neuroendocrine differentiation--an entity of no clinical or prognostic significance. *Am J Surg Pathol*. 2007 Jan;31(1):26-32.
- 123 Rajput AB, Turbin DA, Cheang MC, Voduc DK, Leung S, Gelmon KA, Gilks CB, Huntsman DG. Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases. *Breast Cancer Res Treat*. 2008;107:249-57.
- 124 Alkushi A, Clarke BA, Akbari M, Makretsov N, Lim P, Miller D, Magliocco A, Coldman A, van de Rijn M, Huntsman D, Parker R, Gilks CB. Identification of prognostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis of immunostaining data. *Mod Pathol*. 2007 Nov;20(11):1156-65.
- 125 Turbin DA, Leung S, Cheang MC, Kennecke HA, Montgomery KD, McKinney S, Treaba DO, Boyd N, Goldstein LC, Badve S, Gown AM, van de Rijn M, Nielsen TO, Gilks CB, Huntsman DG. Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases. *Breast Cancer Res Treat*. 2008;110:417-26.
- 126 Ota T, Gilks CB, Longacre T, Leung PC, Auersperg N. HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features. *Reprod Sci*. 2007 Sep;14(6):605-14.
- 127 Joshua Z. Press, Alessandro De Luca, Sean Young, Niki Boyd, Armelle Troussard, Yolanda Ridge, Pardeep Kaurah, Steve E. Kalloger, Margaret Smith, Paul T. Spellman, Yuker Wang, Dianne M. Miller,

- Doug Horsman, Malek Faham, C. Blake Gilks, Joe Gray, David G. Huntsman. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. *BMC Cancer* 2008;8:17.
- 128 Joshua Z. Press, Jennifer A. Kenyon, Blaise A. Clarke, Hui Xue, Dmitry Turbin, Melinda A. Miller, Alessandro De Luca, Dianne M. Miller, David G. Huntsman, C. Blake Gilks, Y.Z. Wang. Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy. *Gynecol Oncol* 2008;110:256-64.
- 129 Michelle M.M. Woo¹, Clara M. Salamanca¹, Melinda Miller^{2,3}, Jaime Symowicz⁴, Peter C.K. Leung¹, Carla Oliveira⁵, Thomas G. Ehlen², C. Blake Gilks^{2,3}, David Huntsman^{2,3}, and Nelly Auersperg. Serous borderline ovarian tumors in long-term culture: phenotypic and genotypic distinction from invasive ovarian carcinomas. *Int J Gynecol Cancer* 2008;18:1234-47.
- 130 Leah M Prentice^{1,2}, Christian Klausen³, Steve Kalloger^{1,2}, Martin Köbel^{2,4}, Steven McKinney¹, Jennifer L Santos^{5,6}, Challayne Kenney², Erika Mehl², C Blake Gilks², Peter Leung³, Ken Swenerton^{7,8}, David G Huntsman^{2*} and Samuel AJ Aparicio. Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma. *BMC Medicine* 2007;Nov 15:5:33.
- 131 C.B. Gilks¹, D.N.Ionescu¹, S.E. Kalloger¹, M. Köbel^{1,2}, J. Irving¹, B. Clarke¹, J. Santos³, N. Le⁴, V. Moravan⁵, K. Swenerton, Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. *Human Pathol* 2008;39:1239-51.
- 132 Turashvili G, Hayes M, Gilks B, Watson P, Aparicio S. Are columnar cell lesions the earliest histologically detectable non-obligate precursor of breast cancer? *Virchows Arch.* 2008;2008:589-98.
- 133 Beck AH, Espinosa I, Gilks CB, van de Rijn M, West RB. The fibromatosis signature defines a robust stromal response in breast carcinoma. *Lab Invest.* 2008;88:591-601.
- 134 Lee CH, Espinosa I, Vrijaldenhoven S, Subramanian S, Montgomery KD, Zhu S, Marinelli RJ, Peterse JL, Poulin N, Nielsen TO, West RB, Gilks CB, van de Rijn M. Prognostic significance of macrophage infiltration in leiomyosarcomas. *Clin Cancer Res.* 2008 Mar 1;14(5):1423-30.
- 135 Brown LA, Kalloger SE, Miller MA, Shih leM, McKinney SE, Santos JL, Swenerton K, Spellman PT, Gray J, Gilks CB, Huntsman DG. Amplification of 11q13 in ovarian carcinoma. *Genes Chromosomes Cancer.* 2008 Jun;47(6):481-9.
- 136 Woo MM, Salamanca CM, Symowicz J, Stack MS, Miller DM, Leung PC, Gilks CB, Auersperg N. SV40 early genes induce neoplastic properties in serous borderline ovarian tumor cells. *Gynecol Oncol.* 2008;111:125-31.
- 137 Auersperg N, Woo MM, Gilks CB. The origin of ovarian carcinomas: A developmental view. *Gynecol Oncol.* 2008;110:452-4.
- 138 Salvador S, Rempel A, Soslow RA, Gilks B, Huntsman D, Miller D. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma. *Gynecol Oncol.* 2008;110:408-17.
- 139 Kobel M, Huntsman DG, Gilks CB. Critical molecular abnormalities in high-grade serous carcinomas of the ovary. *Expert Rev Mol Med* 2008;Aug 1;10:e22.
- 140 Jensen KC, Turbin DA, Leung S, Miller MA, Johnson K, Norris B, Hastie T, McKinney S, Nielsen TO, Huntsman DG, Gilks CB, West RB. New cutpoints to identify increased HER2 copy number: analysis of a large, population-based cohort with long-term follow-up. *Breast Cancer Res Treat.* 2008;112:453-9.
- 141 Wong MP, Cheang M, Yorida E, Coldman A, Gilks CB, Huntsman D, Berean K. Loss of desmoglein 1 expression associated with worse prognosis in head and neck squamous cell carcinoma patients. *Pathology.* 2008 Oct;40(6):611-6.
- 142 Ronnett BM, Yemelyanova AV, Vang R, Gilks CB, Miller D, Gravitt PE, Kurman RJ. Endocervical adenocarcinomas with ovarian metastases: analysis of 29 cases with emphasis on minimally invasive cervical tumors and the ability of the metastases to simulate primary ovarian neoplasms. *Am J Surg Pathol.* 2008 Dec;32(12):1835-53.
- 143 Jensen KC, Schaeffer DF, Cheang M, Montgomery K, West RB, Gilks CB, Ross D, Turashvili G, Schnitt S, van de Rijn M. Characterization of a novel anti-fatty acid synthase (FASN) antiserum in breast tissue. *Mod Pathol.* 2008 Dec;21(12):1413-20.
- 144 Köbel M, Kalloger SE, Carrick J, Huntsman D, Asad H, Oliva E, Ewanowich CA, Soslow RA, Gilks CB. A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. *Am J Surg Pathol.* 2009 Jan;33(1):14-21.

- 145 Milne K, Barnes RO, Girardin A, Mawer MA, Nesslinger NJ, Ng A, Nielsen JS, Sahota R, Tran E, Webb JR, Wong MQ, Wick DA, Wray A, McMurtrie E, Köbel M, Kalloger SE, Gilks CB, Watson PH, Nelson BH. Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer. *PLoS ONE*. 2008;3(10):e3409. Epub 2008 Oct 15.
- 146 Köbel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice LM, Miller D, Santos J, Swenerton K, Gilks CB, Huntsman D. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. *PLoS Med*. 2008 Dec 2;5(12):e232.
- 147 Clarke B, Tinker AV, Lee CH, Subramanian S, van de Rijn M, Turbin D, Kalloger S, Han G, Ceballos K, Cadungog MG, Huntsman DG, Coukos G, Gilks CB. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. *Mod Pathol*. 2009;22:393-402.
- 148 Köbel M, Xu H, Bourne PA, Spaulding BO, Shih IM, Mao TL, Soslow RA, Ewanowich CA, Kalloger SE, Mehl E, Lee CH, Huntsman D, Gilks CB. IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. *Mod Pathol*. 2009;22:469-475.
- 149 Chia S, Norris B, Speers C, Cheang M, Gilks B, Gown AM, Huntsman D, Olivetto IA, Nielsen TO, Gelmon K. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. *J Clin Oncol*. 2008 Dec 10;26(35):5697-704.
- 150 Salvador S, Gilks B, Köbel M, Huntsman D, Rosen B, Miller D. The fallopian tube: primary site of most pelvic high-grade serous carcinomas. *Int J Gynecol Ca* 2009;19:58-64.
- 151 Turashvili G, Leung S, Turbin D, Montgomery K, Gilks B, West R, Carrier M, Huntsman D, Aparicio S. Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization (FISH): pathologist assessment compared to quantitative image analysis. *BMC Cancer*. 2009 May 29;9:165.
- 152 Liu P, Khurana A, Rattan R, He X, Kalloger S, Dowdy S, Gilks B, Shridhar V. Regulation of HSulf-1 expression by variant hepatic nuclear factor 1 in ovarian cancer. *Cancer Res*. 2009 Jun 1;69(11):4843-50.
- 153 Renouf DJ, Wood-Baker R, Ionescu DN, Leung S, Masoudi H, Gilks CB, Laskin J. BCL-2 expression is prognostic for improved survival in non-small cell lung cancer. *J Thorac Oncol*. 2009 Apr;4(4):486-91.
- 154 Terry J, Torlakovic EE, Garratt J, Miller D, Köbel M, Cooper J, Bahzad S, Pilavdzic D, O'Malley F, O'Brien AE, Sengupta S, Alport E, Têtu B, Knight B, Pettigrew NM, Berendt R, Wolber R, Trotter MJ, Riddell RH, Gaboury L, Elms F, Magliocco A, Barnes P, Gown AM, Gilks CB. Implementation of a Canadian External Quality Assurance Program for Breast Cancer Biomarkers: An Initiative of Canadian Quality Control in Immunohistochemistry (ciQc) and Canadian Association of Pathologists (CAP) National Standards Committee/Immunohistochemistry. *Appl Immunohistochem Mol Morphol*. 2009 Apr 9. [Epub ahead of print]
- 155 Espinosa I, Beck AH, Lee CH, Zhu S, Montgomery KD, Marinelli RJ, Ganjoo KN, Nielsen TO, Gilks CB, West RB, van de Rijn M. Coordinate expression of colony-stimulating factor-1 and colony-stimulating factor-1-related proteins is associated with poor prognosis in gynecological and nongynecological leiomyosarcoma. *Am J Pathol*. 2009 Jun;174(6):2347-56.
- 156 Shah SP, Köbel M, Senz J, Morin RD, Clarke BA, Wiegand KC, Leung G, Zayed A, Mehl E, Kalloger SE, Sun M, Giuliani R, Yorida E, Jones S, Varhol R, Swenerton KD, Miller D, Clement PB, Crane C, Madore J, Provencher D, Leung P, DeFazio A, Khattra J, Turashvili G, Zhao Y, Zeng T, Glover JN, Vanderhyden B, Zhao C, Parkinson CA, Jimenez-Linan M, Bowtell DD, Mes-Masson AM, Brenton JD, Aparicio SA, Boyd N, Hirst M, Gilks CB, Marra M, Huntsman DG. Mutation of FOXL2 in granulosa-cell tumors of the ovary. *N Engl J Med*. 2009 Jun 25;360(26):2719-29.
- 157 Gilks CB, Prat J. Ovarian carcinoma pathology and genetics: recent advances. *Hum Pathol*. 2009;40:1213-23.
- 158 Milne K, Köbel M, Kalloger SE, Barnes RO, Gao D, Gilks CB, Watson PH, Nelson BH. Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. *PLoS One*. 2009 Jul 29;4(7):e6412.
- 159 Lee CH, Turbin DA, Sung YC, Espinosa I, Montgomery K, van de Rijn M, Gilks CB. A panel of antibodies to determine site of origin and malignancy in smooth muscle tumors. *Mod Pathol*. 2009 Dec;22(12):1519-31.
- 160 Lee CH, Subramanian S, Beck AH, Espinosa I, Senz J, Zhu SX, Huntsman D, van de Rijn M, Gilks CB. MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary. *PLoS One*. 2009 Oct 2;4(10):e7314.

- 161 Köbel M, Kalloger SE, Santos JL, Huntsman DG, Gilks CB, Swenerton KD. Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications. *Gynecol Oncol*. 2010 Jan;116(1):50-6.
- 162 Schrader KA, Gorbacheva B, Senz J, Heravi-Moussavi A, Melnyk N, Salamanca C, Maines-Bandiera S, Cooke SL, Leung P, Brenton JD, Gilks CB, Monahan J, Huntsman DG. The specificity of the FOXL2 c.402C>G Somatic mutation: a survey of solid tumors. *PLoS One*. 2009 Nov 24;4(11):e7988.
- 163 Köbel M, Gilks CB, Huntsman DG. Adult-type granulosa cell tumors and FOXL2 mutation. *Cancer Res*. 2009 Dec 15;69(24):9160-2.
- 164 McAlpine JN, Wiegand KC, Vang R, Ronnett BM, Adamiak A, Köbel M, Kalloger SE, Swenerton KD, Huntsman DG, Gilks CB, Miller DM. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. *BMC Cancer*. 2009 Dec 10;9:433.
- 165 Gilks CB. Molecular abnormalities in ovarian cancer subtypes other than high-grade serous carcinoma. *J Oncol*. 2010;2010.
- 166 Watson PH, Wilson-McManus JE, Barnes RO, Giesz SC, Png A, Hegele RG, Brinkman JN, Mackenzie IR, Huntsman DG, Junker A, Gilks B, Skarsgard E, Burgess M, Aparicio S, McManus BM. Evolutionary concepts in biobanking - the BC BioLibrary. *J Transl Med*. 2009 Nov 12;7:95.
- 167 Chiu CG, Masoudi H, Leung S, Voduc DK, Gilks B, Huntsman DG, Wiseman SM. HER-3 overexpression is prognostic of reduced breast cancer survival: a study of 4046 patients. *Ann Surg*. 2010 Jun;251(6):1107-16.
- 168 Carey MS, Agarwal R, Gilks B, Swenerton K, Kalloger S, Santos J, Ju Z, Lu Y, Zhang F, Coombes KR, Miller D, Huntsman D, Mills GB, Hennessy BT. Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy. *Clin Cancer Res*. 2010 May 15;16(10):2852-60.
- 169 Torlakovic EE, Riddell R, Banerjee D, El-Zimaity H, Pilavdzic D, Dawe P, Magliocco A, Barnes P, Berendt R, Cook D, Gilks B, Williams G, Perez-Ordóñez B, Wehrli B, Swanson PE, Otis CN, Nielsen S, Vyberg M, Butany J. Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee/Immunohistochemistry: best practice recommendations for standardization of immunohistochemistry tests. Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee. *Am J Clin Pathol*. 2010 Mar;133(3):354-65.
- 170 Maines-Bandiera S, Woo MM, Borugian M, Molday LL, Hii T, Gilks B, Leung PC, Molday RS, Auersperg N. Oviductal glycoprotein (OVGP1, MUC9): a differentiation-based mucin present in serum of women with ovarian cancer. *Int J Gynecol Cancer*. 2010 Jan;20(1):16-22.
- 171 Köbel M, Kalloger SE, Baker PM, Ewanowich CA, Arseneau J, Zhrebitskiy V, Abdulkarim S, Leung S, Duggan MA, Fontaine D, Parker R, Huntsman DG, Gilks CB. Diagnosis of Ovarian Carcinoma Cell Type is Highly Reproducible: A Transcanadian Study. *Am J Surg Pathol*. 2010;34:7:984-993.
- 172 Clarke BA, Gilks CB. Endometrial carcinoma: controversies in histopathological assessment of grade and tumour cell type. *J Clin Pathol*. 2010 May;63(5):410-5.
- 173 Köbel M, Kalloger SE, Huntsman DG, Santos JL, Swenerton KD, Seidman JD, Gilks CB; Cheryl Brown Ovarian Cancer Outcomes Unit of the British Columbia Cancer Agency, Vancouver BC. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. *Int J Gynecol Pathol*. 2010 May;29(3):203-11.
- 174 Tabrizi AD, Kalloger SE, Köbel M, Cipollone J, Roskelley CD, Mehl E, Gilks CB. Primary ovarian mucinous carcinoma of intestinal type: significance of pattern of invasion and immunohistochemical expression profile in a series of 31 cases. *Int J Gynecol Pathol*. 2010 Mar;29(2):99-107.
- 175 Alkushi A, Köbel M, Kalloger SE, Gilks CB. High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes. *Int J Gynecol Pathol*. 2010 Jul;29(4):343-50.
- 176 Mulligan AM, Plotkin A, Rouzbahman M, Soslow RA, Gilks CB, Clarke BA. Endometrial giant cell carcinoma: a case series and review of the spectrum of endometrial neoplasms containing giant cells. *Am J Surg Pathol*. 2010 Aug;34(8):1132-8.
- 177 Köbel M, Reuss A, Bois A, Kommoss S, Kommoss F, Gao D, Kalloger SE, Huntsman DG, Gilks CB. The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. *J Pathol*. 2010 Oct;222(2):191-8.

- 178 Meyer SE, Hasenstein JR, Baktula A, Velu CS, Xu Y, Wan H, Whitsett JA, Gilks CB, Grimes HL. Kruppel-like factor 5 is not required for K-RasG12D lung tumorigenesis, but represses ABCG2 expression and is associated with better disease-specific survival. *Am J Pathol.* 2010 Sep;177(3):1503-13.
- 179 Swenerton KD, Santos JL, Gilks CB, Köbel M, Hoskins PJ, Wong F, Le ND. Histotype predicts the curative potential of radiotherapy: the example of ovarian cancers. *Ann Oncol.* 2010 Aug 6. [Epub ahead of print]
- 180 Pradhan M, Risberg BA, Trope CG, van de Rijn M, Gilks CB, Lee CH. Gross genomic alterations and gene expression profiles of high-grade serous carcinoma of the ovary with and without BRCA1 inactivation. *BMC Cancer.* 2010 Sep 15;10(1):493.
- 181 Copete M, Garratt J, Gilks B, Pilavdzic D, Richard B, Bigras G, Mitchell S, Lining LA, Cheung C, Torlakovic EE. Inappropriate calibration and optimisation of pan-keratin (pan-CK) and low molecular weight keratin (LMWCK) immunohistochemistry tests: Canadian Immunohistochemistry Quality Control (CIQC) experience. *J Clin Pathol.* 2011 Jan 22. [Epub ahead of print]
- 182 Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, Yang W, Heravi-Moussavi A, Giuliany R, Chow C, Fee J, Zayed A, Prentice L, Melnyk N, Turashvili G, Delaney AD, Madore J, Yip S, McPherson AW, Ha G, Bell L, Fereday S, Tam A, Galletta L, Tonin PN, Provencher D, Miller D, Jones SJ, Moore RA, Morin GB, Oloumi A, Boyd N, Aparicio SA, Shih leM, Mes-Masson AM, Bowtell DD, Hirst M, Gilks B, Marra MA, Huntsman DG. ARID1A mutations in endometriosis-associated ovarian carcinomas. *N Engl J Med.* 2010 Oct 14;363(16):1532-43.
- 183 Chiu CG, Masoudi H, Leung S, Voduc DK, Gilks B, Huntsman DG, Wiseman SM. HER-3 overexpression is prognostic of reduced breast cancer survival: a study of 4046 patients. *Ann Surg.* 2010 Jun;251(6):1107-16.
- 184 Carey MS, Agarwal R, Gilks B, Swenerton K, Kalloger S, Santos J, Ju Z, Lu Y, Zhang F, Coombes KR, Miller D, Huntsman D, Mills GB, Hennessy BT. Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy. *Clin Cancer Res.* 2010 May 15;16(10):2852-60.
- 185 Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee, Torlakovic EE, Riddell R, Banerjee D, El-Zimaity H, Pilavdzic D, Dawe P, Magliocco A, Barnes P, Berendt R, Cook D, Gilks B, Williams G, Perez-Ordóñez B, Wehrli B, Swanson PE, Otis CN, Nielsen S, Vyberg M, Butany J. Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee/Immunohistochemistry: best practice recommendations for standardization of immunohistochemistry tests. *Am J Clin Pathol.* 2010 Mar;133(3):354-65.
- 186 Alhejaily A, Wood B, Foster CJ, Farmer PL, Gilks CB, Brettschneider J, Day AG, Feilotter HE, Baetz T, Lebrun DP. Differential expression of cell-cycle regulatory proteins defines distinct classes of follicular lymphoma. *Hum Pathol.* 2011 Feb 1. [Epub ahead of print]
- 187 McAlpine JN, El Hallani S, Lam SF, Kalloger SE, Luk M, Huntsman DG, Macaulay C, Gilks CB, Miller DM, Lane PM. Autofluorescence imaging can identify preinvasive or clinically occult lesions in fallopian tube epithelium: A promising step towards screening and early detection. *Gynecol Oncol.* 2011 Jan 13. [Epub ahead of print]
- 188 DeLair D, Oliva E, Köbel M, Macias A, Gilks CB, Soslow RA. Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: a study of 155 cases. *Am J Surg Pathol.* 2011 Jan;35(1):36-44.
- 189 Kalloger SE, Köbel M, Leung S, Mehl E, Gao D, Marcon KM, Chow C, Clarke BA, Huntsman DG, Gilks CB. Calculator for ovarian carcinoma subtype prediction. *Mod Pathol.* 2010 Dec 3. [Epub ahead of print]
- 190 Kortmann U, McAlpine JN, Xue H, Guan J, Ha G, Tully S, Shafait S, Lau A, Cranston AN, O'Connor MJ, Huntsman DG, Wang Y, Gilks CB. Tumor Growth Inhibition by Olaparib in BRCA2 Germline-Mutated Patient-Derived Ovarian Cancer Tissue Xenografts. *Clin Cancer Res.* 2011 Feb 15;17(4):783-91.
- 191 Hung T, Wolber R, Garratt J, Kalloger S, Gilks CB. Improved breast cancer biomarker detection through a simple, high frequency, low cost external proficiency testing program. *Pathology.* 2010 Dec;42(7):637-42.
- 192 Ota T, Clayton AC, Minot DM, Shridhar V, Hartmann LC, Gilks CB, Chien JR. Minichromosome maintenance protein 7 as a potential prognostic factor for progression-free survival in high-grade serous carcinomas of the ovary. *Mod Pathol.* 2011 Feb;24(2):277-87.
- 193 Derycke MS, Pambuccian SE, Gilks CB, Kalloger SE, Ghidouche A, Lopez M, Bliss RL, Geller MA, Argenta PA, Harrington KM, Skubitz AP. Nectin 4 overexpression in ovarian cancer tissues and serum: potential role as a serum biomarker. *Am J Clin Pathol.* 2010 Nov;134(5):835-45.
- 194 Copete M, Garratt J, **Gilks B**, Pilavdzic D, Berendt R, Bigras G, Mitchell S, Lining LA, Cheung C, Torlakovic EE. Inappropriate calibration and optimisation of pan-keratin (pan-CK) and low molecular

- weight keratin (LMWCK) immunohistochemistry tests: Canadian Immunohistochemistry Quality Control (CIQC) experience. *J Clin Pathol*. 2011 Mar;64(3):220-5.
- 195 Yerushalmi R, Gelmon KA, Leung S, Gao D, Cheang M, Pollak M, Turashvili G, Gilks BC, Kennecke H. Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes. *Breast Cancer Res Treat*. 2011 May 15. [Epub ahead of print]
- 196 Wiegand KC, Lee AF, Al-Agha OM, Chow C, Kalloger SE, Scott DW, Steidl C, Wiseman SM, Gascoyne RD, **Gilks B**, Huntsman DG. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. *J Pathol*. 2011 Jul;224(3):328-33.
- 197 Cheung CC, Neufeld H, Lining LA, Pilavdzic D, Copete M, Garratt J, **Gilks B**, Torlakovic EE. The Laboratory Score/Reference Method Score Ratio (LSRSR) Is a Novel Tool for Monitoring Laboratory Performance in Immunohistochemistry Proficiency Testing of Hormone Receptors in Breast Cancer: The CIQC Experience. *Am J Clin Pathol*. 2011 Jul;136(1):67-73.
- 198 Ryan P, Mulligan AM, Aronson M, Ferguson SE, Bapat B, Semotiuk K, Holter S, Kwon J, Kalloger SE, **Gilks CB**, Gallinger S, Pollett A, Clarke BA. Comparison of clinical schemas and morphologic features in predicting Lynch syndrome in mutation-positive patients with endometrial cancer encountered in the context of familial gastrointestinal cancer registries. *Cancer*. 2011 Jun 30. [Epub ahead of print]
- 199 **Gilks CB**, McAlpine J. Human epidermal growth factor receptor 2 overexpression and amplification in mucinous tumours of ovary. *Histopathology*. 2011 Jun;58(7):1173-4.
- 200 Köbel M, Turbin D, Kalloger SE, Gao D, Huntsman DG, **Gilks CB**. Biomarker Expression in Pelvic High-grade Serous Carcinoma: Comparison of Ovarian and Omental Sites. *Int J Gynecol Pathol*. 2011 Jul;30(4):366-71.
- 201 Boylan KL, Misemer B, Derycke MS, Andersen JD, Harrington KM, Kalloger SE, **Gilks CB**, Pambuccian SE, Skubitz AP. Claudin 4 Is Differentially Expressed between Ovarian Cancer Subtypes and Plays a Role in Spheroid Formation. *Int J Mol Sci*. 2011 Feb 22;12(2):1334-58.
- 202 Kwon JS, Scott JL, **Gilks CB**, Daniels MS, Sun CC, Lu KH. Testing women with endometrial cancer to detect lynch syndrome. *J Clin Oncol*. 2011 Jun 1;29(16):2247-52.
- 203 Huntsman DG, **Gilks CB**. Surgical staging of early stage epithelial ovarian cancer. *Gynecol Oncol*. 2011 Apr 29. [Epub ahead of print]
- 204 Al-Barrak J, Santos JL, Tinker A, Hoskins P, **Gilks CB**, Lau H, Swenerton KD. Exploring palliative treatment outcomes in women with advanced or recurrent ovarian clear cell carcinoma. *Gynecol Oncol*. 2011 Jul;122(1):107-10.
- 205 McConechy MK, Anglesio MS, Kalloger SE, Yang W, Senz J, Chow C, Heravi-Moussavi A, Morin GB, Mes-Masson AM; Australian Ovarian Cancer Study Group, Carey MS, McAlpine JN, Kwon JS, Prentice LM, Boyd N, Shah SP, **Gilks CB**, Huntsman DG. Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. *J Pathol*. 2011 Apr;223(5):567-73.
- 206 Al-Agha OM, Huwait HF, Chow C, Yang W, Senz J, Kalloger SE, Huntsman DG, Young RH, **Gilks CB**. FOXL2 is a sensitive and specific marker for sex cord-stromal tumors of the ovary. *Am J Surg Pathol*. 2011 Apr;35(4):484-94.
- 207 Anglesio MS, George J, Kulbe H, Friedlander M, Rischin D, Lemech C, Power J, Coward J, Cowin PA, House CM, Chakravarty P, Gorringer KL, Campbell IG; Australian Ovarian Cancer Study Group, Okamoto A, Birrer MJ, Huntsman DG, de Fazio A, Kalloger SE, Balkwill F, **Gilks CB**, Bowtell DD. IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. *Clin Cancer Res*. 2011 Apr 15;17(8):2538-48.
- 208 Uterine leiomyosarcomas: tumor size, mitotic index, and biomarkers Ki67, and Bcl-2 identify two groups with different prognosis. D'Angelo E, Espinosa I, Ali R, **Gilks CB**, Rijn M, Lee CH, Prat J. *Gynecol Oncol*. 2011 May 1;121(2):328-33.
- 209 CSF1 expression in nongynecological leiomyosarcoma is associated with increased tumor angiogenesis. Espinosa I, Edris B, Lee CH, Cheng HW, Gilks CB, Wang Y, Montgomery KD, Varma S, Li R, Marinelli RJ, West RB, Nielsen T, Beck AH, van de Rijn M. *Am J Pathol*. 2011 Oct;179(4):2100-7.
- 210 Frequency of known gene rearrangements in endometrial stromal tumors. Chiang S, Ali R, Melnyk N, McAlpine JN, Huntsman DG, Gilks CB, Lee CH, Oliva E. *Am J Surg Pathol*. 2011 Sep;35(9):1364-72. Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. Stany MP, Vathipadiekal V, Ozbun L, Stone RL, Mok SC, Xue H, Kagami T, Wang Y, McAlpine JN, Bowtell D, Gout PW, Miller DM, Gilks CB, Huntsman DG, Ellard SL, Wang YZ, Vivas-Mejia P, Lopez-Berestein G, Sood AK, Birrer MJ. *PLoS One*. 2011;6(7):e21121.

- 211 Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang LP, Gimotty PA, Gilks CB, Lal P, Zhang L, Coukos G. *Nature*. 2011 Jul 13;475(7355):226-30.
- 212 Development of an evidence-based approach to external quality assurance for breast cancer hormone receptor immunohistochemistry: comparison of reference values. Makretsov N, Gilks CB, Alaghebandan R, Garratt J, Quenneville L, Mercer J, Palavdzic D, Torlakovic EE; Canadian Immunohistochemistry Quality Control Program; Canadian Association of Pathologists. *Arch Pathol Lab Med*. 2011 Jul;135(7):874-81.
- 213 Copy number aberrations in benign serous ovarian tumors: a case for reclassification? Hunter SM, Anglesio MS, Sharma R, Gilks B, Melnyk N, Chiew YE, Longacre TA, Defazio A, Huntsman DG, Goringe KL, Campbell IG. *Clin Cancer Res*. 2011 Oct 5. [Epub ahead of print]
- 214 Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A. *Lancet Oncol*. 2011 Sep;12(9):852-61.
- 215 McCluggage WG, Soslow RA, **Gilks CB**. Patterns of p53 immunoreactivity in endometrial carcinomas: 'all or nothing' staining is of importance. *Histopathology*. 2011 Oct;59(4):786-8. *IF=3.569*
- 216 Espinosa I, Edris B, Lee CH, Cheng HW, **Gilks CB**, Wang Y, Montgomery KD, Varma S, Li R, Marinelli RJ, West RB, Nielsen T, Beck AH, van de Rijn M. CSF1 expression in nongynecological leiomyosarcoma is associated with increased tumor angiogenesis. *Am J Pathol*. 2011 Oct;179(4):2100-7. *IF=5.224*
- 217 Chiang S, Ali R, Melnyk N, McAlpine JN, Huntsman DG, **Gilks CB**, Lee CH, Oliva E. Frequency of known gene rearrangements in endometrial stromal tumors. *Am J Surg Pathol*. 2011 Sep;35(9):1364-72. *IF=4.106*
- 218 Makretsov N, **Gilks CB**, Alaghebandan R, Garratt J, Quenneville L, Mercer J, Palavdzic D, Torlakovic EE; Canadian Immunohistochemistry Quality Control Program; Canadian Association of Pathologists. Development of an evidence-based approach to external quality assurance for breast cancer hormone receptor immunohistochemistry: comparison of reference values. *Arch Pathol Lab Med*. 2011 Jul;135(7):874-81. *IF=2.279*
- 219 **Gilks CB**, McAlpine J. Human epidermal growth factor receptor 2 overexpression and amplification in mucinous tumours of ovary. *Histopathology*. 2011 Jun;58(7):1173-4. *IF=3.569*
- 220 Boylan KL, Misemer B, Derycke MS, Andersen JD, Harrington KM, Kalloger SE, **Gilks CB**, Pambuccian SE, Skubitz AP. Claudin 4 Is Differentially Expressed between Ovarian Cancer Subtypes and Plays a Role in Spheroid Formation. *Int J Mol Sci*. 2011 Feb;12(2):1334-58. *IF=2.279*
- 221 Huntsman DG, **Gilks CB**. Surgical staging of early stage epithelial ovarian cancer. *Gynecol Oncol*. 2011 Aug;122(2):460-1. *IF=3.760*
- 222 D'Angelo E, Espinosa I, Ali R, **Gilks CB**, Rijn M, Lee CH, Prat J. Uterine leiomyosarcomas: tumor size, mitotic index, and biomarkers Ki67 and Bcl-2 identify two groups with different prognosis. *Gynecol Oncol*. 2011 May;121(2):328-33. *IF=2.279*
- 223 Alhejaily A, Wood B, Foster CJ, Farmer PL, **Gilks CB**, Brettschneider J, Day AG, Feilotter HE, Baetz T, LeBrun DP. Differential expression of cell-cycle regulatory proteins defines distinct classes of follicular lymphoma. *Hum Pathol*. 2011 Jul;42(7):972-82. *IF=2.998*
- 224 McAlpine JN, El Hallani S, Lam SF, Kalloger SE, Luk M, Huntsman DG, MacAulay C, **Gilks CB**, Miller DM, Lane PM. Autofluorescence imaging can identify preinvasive or clinically occult lesions in fallopian tube epithelium: a promising step towards screening and early detection. *Gynecol Oncol*. 2011 Mar;120(3):385-92. *IF=2.279*
- 225 DeLair D, Oliva E, Kobel M, Macias A, **Gilks CB**, Soslow RA. Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: a study of 155 cases. *Am J Surg Pathol*. 2011 Jan;35(1):36-44. *IF=4.106*
- 226 Ota T, Clayton AC, Minot DM, Shridhar V, Hartmann LC, **Gilks CB**, Chien JR. Minichromosome maintenance protein 7 as a potential prognostic factor for progression-free survival in high-grade serous carcinomas of the ovary. *Mod Pathol*. 2011 Feb;24(2):277-87.
- 227 Swenerton KD, Santos JL, **Gilks CB**, Köbel M, Hoskins PJ, Wong F, Le ND. Histotype predicts the curative potential of radiotherapy: the example of ovarian cancers. *Ann Oncol*. 2011 Feb;22(2):341-7. *IF=6.452*

- 228 Milne K, Alexander C, Webb JR, Sun W, Dillon K, Kalloger SE, **Gilks CB**, Clarke B, Kobel M, Nelson BH. Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes. *J Transl Med*. 2012 Feb;10(1):33. *IF=3.508*
- 229 McAlpine JN, Porter H, Köbel M, Nelson BH, Prentice LM, Kalloger SE, Senz J, Milne K, Ding J, Shah SP, Huntsman DG, **Gilks CB**. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. *Mod Pathol*. 2012 May;25(5):740-50.
- 230 Cipollone JA, Graves ML, Köbel M, Kalloger SE, Poon T, **Gilks CB**, McNagny KM, Roskelley CD. The anti-adhesive mucin podocalyxin may help initiate the transperitoneal metastasis of high grade serous ovarian carcinoma. *Clin Exp Metastasis*. 2012 Mar;29(3):239-52.
- 231 McCluggage WG, Connolly LE, McBride HA, Kalloger S, **Gilks CB**. HMGA2 is commonly expressed in uterine serous carcinomas and is a useful adjunct to diagnosis. *Histopathology*. 2012 Mar;60(4):547-53. *IF=3.569*
- 232 Lee CH, Ou WB, Mariño-Enriquez A, Zhu M, Mayeda M, Wang Y, Guo X, Brunner AL, Amant F, French CA, West RB, McAlpine JN, **Gilks CB**, Yaffe MB, Prentice LM, McPherson A, Jones SJ, Marra MA, Shah SP, van de Rijn M, Huntsman DG, Dal Cin P, Debiec-Rychter M, Nucci MR, Fletcher JA. 14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. *Proc Natl Acad Sci USA*. 2012 Jan;109(3):929-34.
- 233 Heravi-Moussavi A, Anglesio MS, Cheng SW, Senz J, Yang W, Prentice L, Fejes AP, Chow C, Tone A, Kalloger SE, Hamel N, Roth A, Ha G, Wan AN, Maines-Bandiera S, Salamanca C, Pasini B, Clarke BA, Lee AF, Lee CH, Zhao C, Young RH, Aparicio SA, Sorensen PH, Woo MM, Boyd N, Jones SJ, Hirst M, Marra MA, **Gilks B**, Shah SP, Foulkes WD, Morin GB, Huntsman DG. Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. *New Engl J Med*. 2012 Jan;366(3):234-42. *IF 53.298*
- 234 Chiu CG, Chan SK, Fang ZA, Masoudi H, Wood-Baker R, Jones SJ, **Gilks B**, Laskin J, Wiseman SM. Beta-catenin expression is prognostic of improved non-small cell lung cancer survival. *Am J Surg*. 2012 May;203(5):654-9. *IF 2.776*
- 235 Lee CH, Mariño-Enriquez A, Ou W, Zhu M, Ali RH, Chiang S, Amant F, **Gilks CB**, van de Rijn M, Oliva E, Debiec-Rychter M, Dal Cin P, Fletcher JA, Nucci MR. The clinicopathologic features of YWHAE-FAM22 endometrial stromal sarcomas: a histologically high-grade and clinically aggressive tumor. *Am J Surg Pathol*. 2012 May;36(5):641-53. *IF 4.352*
- 236 Hoskins PJ, Le N, **Gilks B**, Tinker A, Santos J, Wong F, Swenerton KD. Low-stage ovarian clear cell carcinoma: population-based outcomes in British Columbia, Canada, with evidence for a survival benefit as a result of irradiation. *J Clin Oncol*. 2012 May;30(14):1656-62. *IF 18.372*
- 237 McConechy MK, Ding J, Cheang MC, Wiegand KC, Senz J, Tone AA, Yang W, Prentice LM, Tse K, Zeng T, McDonald H, Schmidt AP, Mutch DG, McAlpine JN, Hirst M, Shah SP, Lee CH, Goodfellow PJ, **Gilks CB**, Huntsman DG. Use of mutation profiles to refine the classification of endometrial carcinomas. *J Pathol*. 2012 Sep;228(1):20-30. *IF 6.318*
- 238 Oishi H, Klausen C, Bentley GE, Osugi T, Tsutsui K, **Gilks CB**, Yano T, Leung PC. The Human Gonadotropin-Inhibitory Hormone Ortholog RFamide-Related Peptide-3 Suppresses Gonadotropin-Induced Progesterone Production in Human Granulosa Cells. *Endocrinology*. 2012 Jul;153(7):3435-45. *IF 4.459*
- 239 Tone AA, Salvador S, Finlayson SJ, Tinker AV, Kwon JS, Lee CH, Cohen T, Ehlen T, Lee M, Carey MS, Heywood M, Pike J, Hoskins PJ, Stuart GC, Swenerton KD, Huntsman DG, **Gilks CB**, Miller DM, McAlpine JN. The role of the fallopian tube in ovarian cancer. *Clin Adv Hematol Oncol*. 2012 May;10(5):296-306.
- 240 Schrader KA, Hurlburt J, Kalloger SE, Hansford S, Young S, Huntsman DG, **Gilks CB**, McAlpine JN. Germline BRCA1 and BRCA2 Mutations in Ovarian Cancer: Utility of a Histology-Based Referral Strategy. *Obstet Gynecol*. 2012 Aug;120(2Pt1):235-40. *IF 4.730*
- 241 Lu FI, **Gilks CB**, Mulligan AM, Ryan P, Allo G, Sy K, Shaw PA, Pollett A, Clarke BA. Prevalence of Loss of Expression of DNA Mismatch Repair Proteins in Primary Epithelial Ovarian Tumors. *Int J Gynecol Pathol*. 2012 Nov;31(6):524-531.
- 242 Anglesio M, Kommoss S, Tolcher M, Clarke B, Galletta L, Porter H, Damaraju S, Fereday S, Winterhoff B, Kalloger S, Senz J, Yang W, Steed H, Allo G, Ferguson S, Shaw P, Teoman A, Garcia J, Schoolmeester J, Bakkum-Gamez J, Tinker A, Bowtell D, Huntsman D, Gilks C, McAlpine J. Molecular Characterization of Mucinous Ovarian Tumors Supports a Stratified Treatment Approach with HER2 Targeting in 18% of Carcinomas. *J Pathol*. 2012 Aug 16. [Epub ahead of print]
- 243 Chan A, **Gilks B**, Kwon J, Tinker AV. New insights into the pathogenesis of ovarian carcinoma: time to rethink ovarian cancer screening. *Obstet Gynecol*. 2012 Oct;120(4):935-40.

- 244 Mohammad T, Garratt J, Torlakovic E, **Gilks B**, Churg A. Utility of a CEA, CD15, Calretinin, and CK5/6 Panel for Distinguishing Between Mesotheliomas and Pulmonary Adenocarcinomas in Clinical Practice. *Am J Surg Pathol*. 2012 Oct;36(10):1503-8.
- 245 Ali RH, Seidman JD, Luk M, Kalloger S, Gilks CB. Transitional Cell Carcinoma of the Ovary is Related to High-grade Serous Carcinoma and is Distinct From Malignant Brenner Tumor. *Int J Gynecol Pathol*. 2012 Nov;31(6):499-506.
- 246 S Spowart JE, Townsend KN, Huwait H, Eshragh S, West NR, Ries JN, Kalloger S, Anglesio M, Gorski SM, Watson PH, Gilks CB, Huntsman DG, Lum JJ. The Autophagy Protein LC3A Correlates with Hypoxia and is a Prognostic Marker of Patient Survival in Clear Cell Ovarian Cancer. *J Pathol*. 2012 Aug 27. [Epub ahead of print].
- 247 Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates. Gurung A, Hung T, Morin J, Gilks CB. *Histopathology*. 2013 Jan;62(1):59-70.
- 248 Prophylactic Salpingectomy and Delayed Oophorectomy as an Alternative for BRCA Mutation Carriers. Kwon JS, Tinker A, Pansegrau G, McAlpine J, Housty M, McCullum M, Gilks CB. *Obstet Gynecol*. 2012 Dec 7. [Epub ahead of print] PMID:23232752
- 249 It sounded like a good idea at the time. Tone A, McAlpine J, Finlayson S, Gilks CB, Heywood M, Huntsman D, Miller D. *J Obstet Gynaecol Can*. 2012 Dec;34(12):1127-32.
- 250 BRCA1 Immunohistochemical Staining as a Prognostic Indicator in Uterine Serous Carcinoma. Beirne JP, Quinn JE, Maxwell P, Kalloger SE, McAlpine J, Gilks CB, Harley IJ, McCluggage WG. *Int J Gynecol Cancer*. 2012 Dec 7. [Epub ahead of print]
- 251 YWHAЕ-FAM22 endometrial stromal sarcoma: diagnosis by reverse transcription-polymerase chain reaction in formalin-fixed, paraffin embedded tumor. Isphording A, Ali RH, Irving J, Goytain A, Nelnyk N, Hoang LN, Gilks CB, Huntsman DG, Nielsen TO, Nucci MR, Lee CH. *Hum Pathol*. 2012 Nov 15. doi:pii: S0046-8177(12)00291-2. 10.1016/j.humphath.2012.08.007. [Epub ahead of print]
- 252 Endometrial Stromal Sarcomas With Sex Cord Differentiation Are Associated With PHF1 Rearrangement. D'Angelo E, Ali RH, Espinosa I, Lee CH, Huntsman DG, Gilks B, Prat J. *Am J Surg Pathol*. 2012 Dec 1. [Epub ahead of print]
- 253 Old versus new FIGO staging systems in predicting overall survival in patients with uterine leiomyosarcoma: A study of 86 cases. Lim D, Wang WL, Lee CH, Dodge T, Gilks B, Oliva E. *Gynecol Oncol*. 2012 Nov 13. [Epub ahead of print]
- 254 Testing for her2 in breast cancer: current pathology challenges faced in Canada. Hanna W, Barnes P, Berendt R, Chang M, Magliocco A, Mulligan AM, Rees H, Miller N, Elavathil L, **Gilks B**, Pettigrew N, Pilavdzic D, Sengupta S. *Curr Oncol*. 2012 Dec;19(6):315-23.
- 255 Interobserver variability in the interpretation of tumor cell necrosis in uterine leiomyosarcoma. Lim D, Alvarez T, Nucci MR, **Gilks B**, Longacre T, Soslow RA, Oliva E. *Am J Surg Pathol*. 2013 May;37(5):650-8.
- 256 Examining the use of salpingectomy with hysterectomy in Canada. Sandoval C, Fung-Kee-Fung M, **Gilks B**, Murphy KJ, Rahal R, Bryant H. *Curr Oncol*. 2013 Jun;20(3):173-5.
- 257 Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. Bashashati A, Ha G, Tone A, Ding J, Prentice LM, Roth A, Rosner J, Shumansky K, Kalloger S, Senz J, Yang W, McConechy M, Melnyk N, Anglesio M, Luk MT, Tse K, Zeng T, Moore R, Zhao Y, Marra MA, **Gilks B**, Yip S, Huntsman DG, McAlpine JN, Shah SP. *J Pathol*. 2013 Sep;231(1):21-34.
- 258 Biomarker-based ovarian carcinoma typing: a histological investigation in the Ovarian Tumor Tissue Analysis consortium. Koebel M, Kalloger S, Lee S, Duggan MA, Kelemen LE, Prentice L, Kalli KR, Fridley BL, Visscher DW, Keeney GA, Vierkant RA, Cunningham JM, Chow C, Ness RB, Moysich KB, Edwards RP, Modugno F, Bunker CH, Wozniak EL, Benjamin E, Gayther SA, Gentry-Maharaj A, Menon U, **Gilks B**, Huntsman DG, Ramus SJ, Goode EL. *Cancer Epidemiol Biomarkers Prev*. 2013 Jul 23. [Epub ahead of print].
- 259 Progesterone receptors induce FOXO1-dependent senescence in ovarian cancer cells. Diep CH, Charles NJ, **Gilks CB**, Kalloger SE, Argenta PA, Lange CA. *Cell Cycle*. 2013 May 1;12(9):1433-49.
- 260 Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma. **Gilks CB**, Oliva E, Soslow RA. *Am J Surg Pathol*. 2013 Jun;37(6):874-81
- 261 Integrated genomic characterization of endometrial carcinoma. Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L, Zhang W, Mills GB, Kucherlapati R, Mardis ER, Levine DA. *Nature*. 2013 May 2;497(7447):67-73.

- 262 Opportunistic salpingectomy for women at low risk for development of ovarian carcinoma: the time has come. **Gilks CB**, Miller D. *Gynecol Oncol*. 2013 Jun;129(3):443-4.
- 263 Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles. McConechy MK, Ding J, Senz J, Yang W, Melnyk N, Tone AA, Prentice LM, Wiegand KC, McAlpine JN, Shah SP, Lee CH, Goodfellow PJ, **Gilks CB**, Huntsman DG. *Mod Pathol*. 2013 Jun 14. doi: 10.1038/modpathol.2013.107. [Epub ahead of print]
- 264 Academic and nonacademic laboratories perform equally on CIQC immunohistochemistry proficiency testing. Chen ZW, Neufeld H, Copete MA, Garratt J, **Gilks CB**, Torlakovic EE. *Am J Clin Pathol*. 2013 Jul;140(1):55-60.
- 265 Ovarian Cellular Fibromas Lack FOXL2 Mutations: A Useful Diagnostic Adjunct in the Distinction From Diffuse Adult Granulosa Cell Tumor. McCluggage WG, Singh N, Kommos S, Huntsman DG, **Gilks CB**. *Am J Surg Pathol*. 2013 Jun 14. [Epub ahead of print]
- 266 Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Sieh W, Köbel M, Longacre TA, Bowtell DD, Defazio A, Goodman MT, Høgdall E, Deen S, Wentzensen N, Moysich KB, Brenton JD, Clarke BA, Menon U, **Gilks CB**, Kim A, Madore J, Fereday S, George J, Galletta L, Lurie G, Wilkens LR, Carney ME, Thompson PJ, Matsuno RK, Kjær SK, Jensen A, Høgdall C, Kalli KR, Fridley BL, Keeney GL, Vierkant RA, Cunningham JM, Brinton LA, Yang HP, Sherman ME, García-Closas M, Lissowska J, Odunsi K, Morrison C, Lele S, Bshara W, Sucheston L, Jimenez-Linan M, Driver K, Alsop J, Mack M, McGuire V, Rothstein JH, Rosen BP, Bernardini MQ, Mackay H, Oza A, Wozniak EL, Benjamin E, Gentry-Maharaj A, Gayther SA, Tinker AV, Prentice LM, Chow C, Anglesio MS, Johnatty SE, Chenevix-Trench G, Whittemore AS, Pharoah PD, Goode EL, Huntsman DG, Ramus SJ. *Lancet Oncol*. 2013 Aug;14(9):853-62.
- 267 ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas. Allo G, Bernardini MQ, Wu RC, Shih IM, Kalloger S, Pollett A, **Gilks CB**, Clarke BA. *Mod Pathol*. 2013 Jul 26. doi: 10.1038/modpathol.2013.144. [Epub ahead of print]
- 268 Kommos S, **Gilks CB**, Kommos F, Chow C, Hilpert F, du Bois A, Köbel M, Huntsman DG, Anglesio M, Kalloger SE, Pfisterer J. Accelerating type-specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (COSP) is a reliable high-throughput tool for case review. *Histopathology*. 2013 Nov;63(5):704-12.
- 269 Ali RH, Kalloger SE, Santos JL, Swenerton KD, **Gilks CB**. Stage II to IV low-grade serous carcinoma of the ovary is associated with a poor prognosis: a clinicopathologic study of 32 patients from a population-based tumor registry. *Int J Gynecol Pathol*. 2013 Nov;32(6):529-35.
- 270 Hoang LN, McConechy MK, Köbel M, Han G, Rouzbahman M, Davidson B, Irving J, Ali RH, Leung S, McAlpine JN, Oliva E, Nucci MR, Soslow RA, Huntsman DG, **Gilks CB**, Lee CH. Histotype-genotype correlation in 36 high-grade endometrial carcinomas. *Am J Surg Pathol*. 2013 Sep;37(9):1421-32.
- 271 DeLair D, Han G, Irving JA, Leung S, Ewanowich CA, Longacre TA, **Gilks CB**, Soslow RA. HNF-1 β in ovarian carcinomas with serous and clear cell change. *Int J Gynecol Pathol*. 2013 Nov;32(6):541-6.
- 272 McAlpine JN, Hanley GE, Woo MM, Tone AA, Rozenberg N, Swenerton KD, **Gilks CB**, Finlayson SJ, Huntsman DG, Miller DM; British Columbia's Ovarian Cancer Research Program (OVCARE). Opportunistic Salpingectomy: Uptake, Risks and Complications of a Regional Initiative for Ovarian Cancer Prevention. *Am J Obstet Gynecol*. 2014 May;210(5):471.e1-11.
- 273 Hoang LN, Han G, McConechy M, Lau S, Chow C, **Gilks CB**, Huntsman DG, Köbel M, Lee CH. Immunohistochemical characterization of prototypical endometrial clear cell carcinoma-diagnostic utility of HNF-1 β and oestrogen receptor. *Histopathology*. 2014 Mar;64(4):585-96.
- 274 McCluggage WG, Staats PN, **Gilks CB**, Clement PB, Young RH. Luteinized thecomas (thecomatosis) associated with sclerosing peritonitis exhibit positive staining with sex cord markers steroidogenic factor-1 (SF-1) and FOXL2. *Am J Surg Pathol*. 2013 Sep;37(9):1458-9.
- 275 Kumar A, **Gilks CB**, Mar C, Santos J, Tinker AV. Patterns of spread of clear cell ovarian cancer: Case report and case series. *Gynecol Oncol Case Rep*. 2013 Aug 3;6:25-7.
- 276 Singh N, **Gilks CB**, Huntsman DG, Smith JH, Coutts M, Ganesan R, McCluggage WG. Adult granulosa cell tumour-like areas occurring in ovarian epithelial neoplasms: report of a case series with investigation of FOXL2 mutation status. *Histopathology*. 2013 Oct 19. [Epub ahead of print]
- 277 Chui MH, **Gilks CB**, Cooper K, Clarke BA. Identifying Lynch syndrome in patients with ovarian carcinoma: the significance of tumor subtype. *Adv Anat Pathol*. 2013 Nov;20(6):378-86.
- 278 Köbel M, Bak J, Bertelsen BI, Carpen O, Grove A, Hansen ES, Levin Jakobsen AM, Lidang M, Måsbäck

- A, Tolf A, **Gilks CB**, Carlson JW. Ovarian Carcinoma Histotype Determination is Highly Reproducible, and Is Improved Through the Use of Immunohistochemistry. *Histopathology* 2014 Jun;64(7):1004-13.
- 279 Ervine A, Leung S, **Gilks CB**, McCluggage WG. Thyroid transcription factor-1 (TTF-1) immunoreactivity is an adverse prognostic factor in endometrioid adenocarcinoma of the uterine corpus. *Histopathology* 2014 May;64(6):840-6.
- 280 Kommos S, **Gilks CB**, Penzel R, Herpel E, Mackenzie R, Huntsman D, Schirmacher P, Anglesio M, Schmidt D, Kommos F. A current perspective on the pathological assessment of FOXL2 in adult-type granulosa cell tumours of the ovary. *Histopathology*. 2014 Feb;64(3):380-8.
- 281 Hoang LN, Ali RH, Lau S, **Gilks CB**, Lee CH. Immunohistochemical Survey of Mismatch Repair Protein Expression in Uterine Sarcomas and Carcinosarcomas. *Int J Gynecol Pathol*. 2014 Sep;33(5):483-491.
- 282 Ha G, Roth A, Khattri J, Ho J, Yap D, Prentice LM, Melnyk N, McPherson A, Bashashati A, Laks E, Biele J, Ding J, Le A, Rosner J, Shumansky K, Marra MA, **Gilks CB**, Huntsman DG, McAlpine JN, Aparicio S, Shah SP. TITAN: Inference of copy number architectures in clonal cell populations from tumor whole genome sequence data. *Genome Res*. 2014 Jul 24. pii: gr.180281.114. [Epub ahead of print]
- 283 Gleicher N, McAlpine JN, **Gilks CB**, Kushnir VA, Lee HJ, Wu YG, Lazzaroni-Tealdi E, Barad DH. Absence of BRCA/FMR1 Correlations in Women with Ovarian Cancers. *PLoS One*. 2014 Jul 18;9(7):e102370.
- 284 Chui MH, Ryan P, Radigan J, Ferguson SE, Pollett A, Aronson M, Semotiuk K, Sy K, Kwon JS, Soma A, Singh N, Gallinger S, Shaw P, Arseneau J, Foulkes WD, **Gilks CB**, Clarke BA. The Histomorphology of Lynch Syndrome-associated Ovarian Carcinomas: Toward a Subtype-specific Screening Strategy. *Am J Surg Pathol*. 2014 Sep;38(9):1173-81.
- 285 Singh N, Leen SL, Han G, Faruqi A, Kokka F, Rosenthal A, Jiang XR, Kim R, McAlpine JN, **Gilks CB**. Expanding the Morphologic Spectrum of Differentiated VIN (dVIN) Through Detailed Mapping of Cases With p53 Loss. *Am J Surg Pathol*. 2014 Jul 14. [Epub ahead of print]
- 286 **Gilks CB**. Mutations in oncogenes: context matters. *Gynecol Oncol*. 2014 Jul;134(1):1-2.
- 287 Singh N, **Gilks CB**, Wilkinson N, McCluggage WG. Assignment of primary site in high-grade serous tubal, ovarian and peritoneal carcinoma: a proposal. *Histopathology*. 2014 Aug;65(2):149-54.
- 288 Bookman MA, **Gilks CB**, Kohn EC, Kaplan KO, Huntsman D, Aghajanian C, Birrer MJ, Ledermann JA, Oza AM, Swenerton KD. Better therapeutic trials in ovarian cancer. *J Natl Cancer Inst*. 2014 Apr;106(4):dju029.
- 289 Aulmann S, Sinn HP, Penzel R, **Gilks CB**, Schott S, Hassel JC, Schmidt D, Kommos F, Schirmacher P, Kommos S. Comparison of molecular abnormalities in vulvar and vaginal melanomas. *Mod Pathol*. 2014 Mar 7. [Epub ahead of print]
- 290 McAlpine JN, Hanley GE, Woo MM, Tone AA, Rozenberg N, Swenerton KD, **Gilks CB**, Finlayson SJ, Huntsman DG, Miller DM. Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention. *Am J Obstet Gynecol*. 2014 May;210(5):471.e1-11.
- 291 Kumar A, **Gilks CB**, Mar C, Santos J, Tinker AV. Patterns of spread of clear cell ovarian cancer: Case report and case series. *Gynecol Oncol Case Rep*. 2013 Aug 3;6:25-7.
- 292 A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation. Wiegand KC, Hennessy BT, Leung S, Wang Y, Ju Z, McGahren M, Kalloger SE, Finlayson S, Stemke-Hale K, Lu Y, Zhang F, Anglesio MS, **Gilks B**, Mills GB, Huntsman DG, Carey MS. *BMC Cancer*. 2014 Feb 22;14:120.
- 293 Standardization of negative controls in diagnostic immunohistochemistry: recommendations from the international ad hoc expert panel. Torlakovic EE, Francis G, Garratt J, **Gilks B**, Hyjek E, Ibrahim M, Miller R, Nielsen S, Petcu EB, Swanson PE, Taylor CR, Vyberg M. *Appl Immunohistochem Mol Morphol*. 2014 Apr;22(4):241-52.
- 294 Assessment of a new system for primary site assignment in high-grade serous carcinoma of fallopian tube, ovary and peritoneum. Singh N, **Gilks CB**, Wilkinson N, McCluggage WG. *Histopathology*. 2015 Jan 14. [Epub ahead of print].
- 295 Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas. McConechy MK, Talhouk A, Li-Chang HH, Leung S, Huntsman DG, **Gilks CB**, McAlpine JN. *Gynecol Oncol*. 2015 Jan 28. [Epub ahead of print].
- 296 FOXL2 Mutation is Absent in Uterine Tumors Resembling Ovarian Sex Cord Tumors. Chiang S, Staats PN, Senz J, Kommos F, De Nictolis M, Huntsman DG, **Gilks CB**, Oliva E. *Am J Surg Pathol*. 2015 Jan 9.

- [Epub ahead of print].
- 297 Costs and benefits of opportunistic salpingectomy as an ovarian cancer prevention strategy. Kwon JS, McAlpine JN, Hanley GE, Finlayson SJ, Cohen T, Miller DM, **Gilks CB**, Huntsman DG. *Obstet Gynecol*. 2015 Feb;125(2):338-45.
- 298 Loss of Sprout2 in human high-grade serous ovarian carcinomas promotes EGF-induced E-cadherin down-regulation and cell invasion. So WK, Cheng JC, Fan Q, Wong AS, Huntsman DG, **Gilks CB**, Leung PC. *FEBS Lett*. 2015 Jan 30;589(3):302-9.
- 299 Incidental Nonuterine High-grade Serous Carcinomas Arise in the Fallopian Tube in Most Cases: Further Evidence for the Tubal Origin of High-grade Serous Carcinomas. **Gilks CB**, Irving J, Köbel M, Lee C, Singh N, Wilkinson N, McCluggage WG. *Am J Surg Pathol*. 2014 Dec 16. [Epub ahead of print].
- 300 Human epidermal growth factor receptor 2 testing in primary breast cancer in the era of standardized testing: a Canadian prospective study. Hanna WM, Barnes PJ, Chang MC, **Gilks CB**, Magliocco AM, Rees H, Quenneville L, Robertson SJ, SenGupta SK, Nofech-Mozes S. *J Clin Oncol*. 2014 Dec 10;32(35):3967-73.
- 301 HER2/neu testing in gastric cancer by immunohistochemistry: assessment of interlaboratory variation. Sheffield BS, Garratt J, Kaloger SE, Li-Chang HH, Torlakovic EE, **Gilks CB**, Schaeffer DF. *Arch Pathol Lab Med*. 2014 Nov;138(11):1495-502.
- 302 Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee for High Complexity Testing/Immunohistochemistry: guidelines for the preparation, release, and storage of unstained archived diagnostic tissue sections for immunohistochemistry. Cheung CC, Banerjee D, Barnes PJ, Berendt RC, Butany J, Canil S, Clarke BA, El-Zimaity H, Garratt J, Geldenhuys L, **Gilks CB**, Manning L, Mengel M, Perez-Ordóñez B, Pilavdzic D, Riddell R, Swanson PE, Torlakovic EE. *Am J Clin Pathol*. 2014 Nov;142(5):629-33.
- 303 Targeted mutation analysis of endometrial clear cell carcinoma. Hoang LN, McConechy MK, Meng B, McIntyre JB, Ewanowich C, **Gilks CB**, Huntsman DG, Köbel M, Lee CH. *Histopathology*. 2014 Oct 12 [Epub ahead of print].
- 304 Current morphologic criteria perform poorly in identifying hereditary leiomyomatosis and renal cell carcinoma syndrome-associated uterine leiomyomas. Alsolami S, El-Bahrawy M, Kaloger SE, AIDaoud N, Pathak TB, Cheung CT, Mulligan AM, Tomlinson IP, Pollard PJ, **Gilks CB**, McCluggage WG, Clarke BA. *Int J Gynecol Pathol*. 2014 Nov;33(6):560-7.
- 305 Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas. Tone AA, McConechy MK, Yang W, Ding J, Yip S, Kong E, Wong KK, Gershenson DM, Mackay H, Shah S, **Gilks B**, Tinker AV, Clarke B, McAlpine JN, Huntsman D. *BMC Cancer*. 2014 Dec 18;14:982.
- 306 Loss of the Notch effector RBPJ promotes tumorigenesis. Kulic I, Robertson G, Chang L, Baker JH, Lockwood WW, Mok W, Fuller M, Fournier M, Wong N, Chou V, Robinson MD, Chun HJ, **Gilks B**, Kempkes B, Thomson TA, Hirst M, Minchinton AI, Lam WL, Jones S, Marra M, Karsan A. *J Exp Med*. 2015 Jan 12;212(1):37-52.
- 307 Standardization of positive controls in diagnostic immunohistochemistry: recommendations from the International Ad Hoc Expert Committee. Torlakovic EE, Nielsen S, Francis G, Garratt J, **Gilks B**, Goldsmith JD, Hornick JL, Hyjek E, Ibrahim M, Miller K, Petcu E, Swanson PE, Zhou X, Taylor CR, Vyberg M. *Appl Immunohistochem Mol Morphol*. 2015 Jan;23(1):1-18

2. **NON-REFEREED PUBLICATIONS**

(a) *Journals*

1. Irving, J., Gilks, C.B. "Endometrial hyperlasia vs adenocarcinoma: an update". Canadian Association of Pathologists Newsletter, 2001.

(b) *Conference Proceedings*

(c) *Other*

3. **BOOKS**

(a) *Authored*

(b) *Edited*

(c) *Chapters*

Invited contributor to Pathology and Genetics of Tumors of the Breast and Female Genital Organs (F. Tavassoli and M. Stratton, editors) in the World Health Organization series on histopathological and genetic criteria for classification of tumors. (2003)

Invited contributor (with Dr. T. Longacre) to write 2 chapters on non-neoplastic disorders of ovary and surface epithelial tumors of ovary in **Gynecologic Pathology**, from the series "Foundations in Diagnostic Pathology" (J. Goldblum ed.), 2009.

Invited contributor to write 2 chapters on surface epithelial tumors of the ovary and serous tumors of the ovary, for **Diagnostic Pathology of Ovarian Tumors** (R. Soslow and C. Tornos eds.) 2011

Invited contributor to write 24 chapters in the on-line and print text Gynecologic Pathology (E. Oliva and M, Nucci eds.) 2014

Invited contributor to Pathology and Genetics of Tumors of the Female Genital Organs in the World Health Organization series on histopathological and genetic criteria for classification of tumors. (2014)

Co-author with P Clement, Chapter on Ovary, Histology for Pathologists (S Mills ed) 2013

Co-author with P Clement and R Young, Chapter on Ovarian Surface Epithelial Neoplasms, in Sternberg's Textbook of Surgical Pathology (S Mills, editor) 2014

Author, Chapter on Pathology of Gynecological Cancer, in textbook Pelvic Cancer Surgery (HR Patel ed) 2015